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ABSTRACT 
INVESTIGATION OF PHOSPHOSERINE AMINOTRANSFERASE 1(PSAT1) IN 
BREAST CANCER PROGRESSION 
 
Stephanie Metcalf 
August 23, 2019 
 
 This dissertation describes my research into the involvement of 
phosphoserine aminotransferase 1 (PSAT1) in breast cancer progression; 
specifically, in triple negative breast cancer (TNBC) metastasis and endocrine 
resistance in estrogen receptor positive breast cancer (ER+BC). Breast cancer is 
the most common tumor diagnosis among women. While the overall 5-year 
survival for breast cancer is reaching 90%, the 5-year survival for metastatic 
disease is only 22%. Metastasis and endocrine resistance combined can affect 
over 50% of patients. One of the proteins and pathways implicated in both 
metastasis and endocrine resistance in breast cancer is phosphoserine 
aminotransferase 1 (PSAT1) and the serine synthetic pathway (SSP). 
 From prior reports and preliminary studies within the lab, I hypothesized that 
PSAT1 may play a role in metastasis within TNBC and contribute to endocrine
vi 
 
within ER+BC. The role of PSAT1 in TNBC metastasis was evaluated via 
examination of the effects of altered PSAT1 expression on metastatic potential in 
TNBC cell lines that were “serine synthesis-independent”. Functional relevance of 
PSAT1 on sensitivity to endocrine therapy was tested in matched endocrine 
sensitive and endocrine resistant cell lines upon alteration of PSAT1 expression. 
Through this work, I found that suppression of PSAT1 significantly inhibited 
the in vitro motility and invasiveness of “serine synthesis-independent” TNBC 
which was not recapitulated upon suppression of PHGDH, which is the first 
enzyme within the SSP. I also found that suppression of PSAT1 reduced the 
number of micro-metastases within the lungs in an experimental metastasis model. 
In addition, I found that both PSAT1 and PHGDH correlated to poorer progression 
free survival in multiple patient cohorts, manipulation of PSAT1 or PHGDH in both 
sensitive and resistant ER+BC cell lines altered sensitivity to 4-hydroxytamoxifen 
treatment. 
This body of work has demonstrated that PSAT1 selectively promotes 
metastasis in “serine synthesis-independent” TNBC via a function unrelated to de 
novo serine synthesis. It also has shown that both PSAT1 and PHGDH contribute 
to tamoxifen resistance in ER+BC and thereby implicating a role for the SSP in this 
context. Taken together, this dissertation demonstrates that PSAT1 contributes to 
breast cancer progression through promotion of TNBC metastasis and ER+BC 
endocrine resistance. 
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CHAPTER 1 
INTRODUCTION 
Breast cancer is the most common malignancy in U.S. women, constituting 
30% of all new cancer diagnoses. As the second leading cause of cancer-related 
deaths in women [1], it comprised 6.8% of all cancer related mortalities in 2016 [2]. 
The lifetime risk for a woman developing breast cancer is currently 1 in 8 or about 
12% [2]. It is estimated that 268,600 women will be diagnosed with invasive breast 
cancer while another 62,930 will be diagnosed with non-invasive breast cancer this 
year [1]. At the beginning of 2019 there were in excess of 3.1 million women in the 
U.S. with a history of breast cancer [1]. These women though all diagnosed with 
breast cancer, do not all have the same disease. Breast cancer has been classified 
into 21 different histological subtypes that can be categorized into four main 
categories based on their hormone receptor (HR) and human epidermal growth 
factor receptor 2 (HER2) status [3]. The four main subtypes are luminal A 
(HR+/HER2-), luminal B (HR+/HER2+), triple negative (HR-/HER2-), and HER2 
enriched (HR-/HER2+) [3]. These all have different clinical presentations, 
oncogenic drivers, treatment options, affected patient populations, and confer 
different patient prognoses [3]. This dissertation will focus on two of these 
subtypes; triple negative breast cancer (TNBC) and luminal A, which will be 
referred to as estrogen receptor positive breast cancer (ER+BC). 
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TNBC is characterized by lack of estrogen receptor-α (ERα), progesterone 
receptor (PR), and HER2 expression [4]. This molecular subtype accounts for 10% 
to 20% of all breast cancer cases [3,5]. It is often considered to be the most 
aggressive with the majority of these tumors being high grade at time of diagnosis 
and basal-like in their appearance [6]. This aggressiveness is especially alarming 
considering the patient populations most commonly diagnosed with this form of 
cancer. TNBC is most common among women under 50 years of age, among 
women that are African American or Hispanic, and among women that harbor 
breast cancer gene 1 (BRAC1) mutations [3,7,8] (Figure 1). The aggressiveness 
of TNBC could be due to its heterogeneous nature and the limited treatment 
options, given that targeted therapies for breast cancer primarily focus on ERα and 
HER2. TNBCs are currently treated with a combination of surgery, chemotherapy 
and radiation [3]. Given the propensity of TNBC to be of a higher grade and more 
aggressive, there is an increased likelihood of metastasis within this subtype [5]. 
 ER+BC is the most common type of breast cancer observed in the clinic, 
accounting for approximately 60% to 75% of all breast cancer diagnoses [9].  
These tumors express ERα and their growth and proliferation is driven by estrogen 
[10]. ER+ tumors are typically slow-growing and found in older patients, as most 
patients with ER+BC are post-menopausal [7]. This subtype also has the best 
prognosis, especially at early stages, due to targeted therapies that have been 
developed [3] (Figure 1). These therapies target different aspects of estrogen 
processing and can be classified into three major categories: aromatase inhibitors, 
selective estrogen receptor modulator (SERM), and selective estrogen receptor 
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Figure 1:  General subtypes of Breast Cancer. This schematic illustrates 
patient outcomes according to breast cancer subtypes. Adapted from Dai et al, 
2015 [8]. Abbreviations: Estrogen Receptor (ER), Progesterone Receptor (PR), 
Human Epidermal Growth Factor Receptor 2 (HER2), Triple Negative Breast 
Cancer (TNBC), Estrogen Receptor Positive Breast Cancer (ER+BC).  
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degraders (SERD), which also has anti-estrogen activity [10]. The different 
categories of endocrine therapy all target estrogen but do so via several different 
mechanisms (Figure 2). Aromatase Inhibitors, such as letrozole, prevent the 
conversion of androgens to estrogens [11]. Tamoxifen is a SERM and its primary 
mechanism of action is through competitive binding against estrogens for the 
estrogen receptor resulting in the inhibition of the estrogen driven pro-proliferative 
transcription program [12,13]. Fulvestrant (ICI 128,780) is a “pure”-antiestrogen or 
SERD [12]. Fulvestrant binds to the estrogen receptor and attenuates estrogen 
signaling through blocking estrogen binding and increased ER protein degradation 
[12]. Tamoxifen was the first of these targeted therapies and became the standard 
first-line therapy in the 1990s [9]. Since its introduction, the mortality rates 
associated with breast cancer have decreased significantly [3]. Much of this trend 
has been attributed to Tamoxifen, and its later designated replacements, that 
target estrogen signaling in ER+ tumors as well as improvements in detection 
methods [3]. 
With these advances in therapies and detection techniques, the current 
overall survival rate for female breast cancer has improved and is approaching 
90%; however, metastatic disease, where the overall 5-year survival rate is 22% 
[2] is still an overwhelming problem. Metastases or advanced recurrent disease 
will develop in approximately 30% of patients despite treatment with standard and 
advanced therapies [14] and is responsible for 90% of breast cancer-related 
deaths [15]. Metastasis occurs when cells disseminate from the primary tumor site  
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Figure 2: Endocrine Therapy Mechanisms of Action. This schematic shows 
the mechanisms of action for common endocrine therapies. Aromatase 
inhibitors inhibit the conversion of testosterone to estrogen. Selective estrogen 
receptor modulators (SERMs), represented by Tamoxifen, compete with 
estrogen for binding to the estrogen receptor and block estrogen signaling. 
Selective estrogen receptor degraders, represented by Fulvestrant, inhibit 
estrogen signaling and unlike SERMs also degrade the estrogen receptor. 
Adapted from Schmid 2017 [9]. 
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and populate a distant site. The common distant sites for breast cancer metastases 
are bone, liver, lung, brain, and lymph nodes, which vary depending on sub-type 
[16]. While metastatic breast cancer can arise from all different breast cancer 
subtypes [17], TNBC is considered the most aggressive as it correlates with poorer 
overall survival in both early stage and metastatic disease [4]. These metastases 
are difficult to treat and unfortunately metastatic disease is often incurable with 
therapies primarily directed at prolonging survival while maximizing quality of life 
[14]. Several clinical trials with either single agent or combinatorial therapies have 
only managed a 3-8 month improvement in overall survival in patients treated with 
the prior standard of care (anthracyclines) [14], underscoring a lack of 
understanding of a complex process involving numerous proteins and pathways. 
 The signaling pathways and processes involved in metastasis are highly 
regulated and together form the metastatic cascade. This is a series of steps that 
a cancer cell must undergo in order to spread from the primary tumor and colonize 
in the secondary site (Figure 3). Metastasis in its earliest form begins with the 
growth of a tumor within the primary organ. This requires a pro-proliferative protein 
signature that promotes genes utilized for growth, proliferation and the necessary 
angiogenesis to support this initial tumor growth [18].  Metastasis truly begins when 
cells disseminate from the primary tumor [19]. This dissemination requires the cells 
to undergo the epithelial to mesenchymal transition (EMT). EMT is a normal 
cellular process that is exploited by the cancer cells in order to promote motility, 
invasion, and other properties that are needed for the cancer cells to extend 
beyond the initial tumor [19].  
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Figure 3: The Metastatic Cascade. This schematic depicts the steps involved 
in metastasis. First, there must be pro-proliferative signals and angiogenesis to 
support the growth of the primary tumor. Cells then undergo EMT which will 
allow for motility and invasion resulting in intravasation into the vasculature. 
Cells within the vasculature need to survive until they arrive at a secondary site. 
The cells then undergo extravasation from the vasculature, revert to their 
epithelial form (MET) and colonize a secondary or metastatic site. Adapted from 
Daves et al, 2011 [18]. 
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EMT is initiated by a group of transcription factors that alter transcription of 
genes that aid in the invasion and motility of cells. These transcription factors 
include Snail, Twist, Slug, and Zeb1 [19]. During EMT, cells change dramatically. 
They typically experience downregulation of epithelial-like markers while 
simultaneously gaining mesenchymal-like markers which includes loss of cell 
polarity and changes in the actin cytoskeleton [20]. In order for a cell to invade into 
the vasculature it needs to degrade the extracellular matrix, which is the role of the 
matrix metalloproteinases (MMPs). The tumor cells control the expression of 
MMPs through several different signaling programs that provide a feed-forward 
mechanism for metastasis as MMPs promote the motility and invasion of cancer 
cells [21]. The promotion of motility and invasion is classically promoted by actin 
cytoskeleton regulation via Rho signaling, integrin signaling, and FAK signaling 
cascades [18].  
Once in the vasculature, tumor cells must survive in circulation before they 
reach a secondary site. According to an established gene signature for metastasis, 
the cell is protected in these conditions by the NRF2 stress response and integrin 
signaling until the cell can exit circulation through the process of extravasation [18]. 
To complete this process, cells must invade through the endothelial wall at the 
secondary site, which is termed transendothelial migration (TEM) [19]. TEM is only 
possible when the endothelial wall has been compromised, a process requiring 
MMPs and VEGF [19]. After extravasation, cells must then colonize a secondary 
site to form a metastatic tumor. The process of colonization is extremely inefficient 
as experimental metastasis models have found that secondary lesions form in only 
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0.01% of instances following injection of tumor cells [19]. This is partially due to 
the strict requirement for the presence of growth factors at the secondary site that 
are necessary for tumor growth [21]. Another determination of whether a cancer 
cell will form a metastatic tumor is the successful completion of the mesenchymal 
to epithelial transition (MET). There is substantial evidence that suggest that 
epithelial cells have a growth advantage in a distant site compared to cells that are 
still mesenchymal [20]. While the general metastatic cascade is known and certain 
pathways have been identified as contributing to metastasis, there is still a lack of 
understanding as to the regulation of the process, especially in regard to unknown 
effectors that can be targeted to either prevent or inhibit metastasis. 
Another clinical challenge for breast cancer patients is resistance to 
therapy. Despite advances in first line treatments, recurrent disease still develops 
in some breast cancer patients. This could be due to dormancy of the disseminated 
cells that occurs due to lack of adaption in the foreign site or lack of nutrient 
availability. Once the cell has adapted to the new environment it can re-enter the 
cell cycle and begin to proliferate again. It could also be due to tumor cells 
becoming resistant to therapeutic agents, such as antiestrogens for ER+ breast 
cancer. While endocrine resistance can ultimately lead to metastatic disease, it 
can also present as recurrence after treatment or as progression of the primary 
disease during initial therapy [11]. This phenomenon affects numerous patients, 
and many will go on to develop resistance to these endocrine therapies. Endocrine 
resistance is acquired at different rates depending on staging and time after 
diagnosis. Within 5 years, 10-15% of early stage ER+ patients will acquire 
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resistance, at 15 years 30% of patients will have recurrent disease despite initial 
response to endocrine therapy. Eventually 40-50% of all ER+ patients will 
experience relapse, while virtually all metastatic ER+ patients will acquire 
resistance in 2-3 years following the start of treatment [22]. The exact mechanisms 
by which endocrine resistance occurs and within what patient population are not 
fully understood.  
However, several mechanisms of endocrine resistance have been 
proposed. One of the mechanisms associated with resistance is dependent upon 
the expression of ERα. It is suggested that innate resistance is associated with 
patients that, while ER+, express lower levels of ERα [22]. In addition, mutations 
in ERα can also lead to resistance. Mutations that lead to constitutive activation of 
ER without the presence of a ligand would allow the cell to be resistant to both 
aromatase inhibitors and antiestrogens [11]. Endocrine resistance has also been 
linked to lack of PR expression in ER+ patients [22].  These patients have a poorer 
overall survival and often have innate resistance to endocrine therapies [22]. 
Resistance is also attributed to several other mechanisms that are not 
associated with the hormone receptors. Altered Tamoxifen metabolism has been 
linked to resistance to Tamoxifen therapy and is reliant upon the patient’s CYP2DG 
allele [11]. Differential growth factor signaling is also implicated in endocrine 
resistance [11,22]. Most ER+ tumors that also express HER2 are resistant to 
endocrine therapy [22]. There is a substantial amount of evidence that supports 
crosstalk between ER, PI3K, AKT, and mTOR and that this association is linked to 
resistance due to aberrant activation of these pathways which reduce levels of ER 
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[11,22]. Studies have shown that patients who responded well to endocrine 
therapy had altered expression of the proteome compared to non-responding 
patients. These changes in expression have been attributed to epigenetic 
regulation of proteins, differences in transcriptional programs, and changes in 
expression levels of the ER coregulatory proteins [11,22]. A large majority of these 
proteins control the cell cycle or are associated with metabolism [22]. 
Altered metabolism has been deemed one of the hallmarks of cancer [23]. 
The differential metabolism associated with cancer cells not only contributes to 
initial tumorigenesis but has been established as a factor in therapy resistance and 
metastasis [24]. The notion that cancer cells differently utilize the metabolic 
processes was first proposed by Dr. Otto Warburg when he noted in the early 
1920s that cancer cells preferentially metabolize glucose to lactate even in the 
presence of oxygen for oxidative phosphorylation (Warburg effect) [25,26]. These 
changes in metabolism allow the cell to use the fuel sources available to them in 
nutrient-limiting conditions present in the tumor microenvironment in order to 
continue to proliferate and survive [24]. Tumors exploit metabolic pathways, 
namely glycolysis, by increasing the expression or activity of transporters and 
enzymes responsible for catalyzing the different metabolic reactions in order to 
generate building blocks (lipids, amino acid, and nucleotides) needed to sustain 
proliferation [24]. In glycolysis, this is achieved via an upregulation of the glucose 
transporters to increase glucose uptake coupled with upregulation of glycolytic 
enzymes or expression of alternative cancer-specific isoforms (i.e. hexokinase 2) 
in order to increase flux through the glycolytic pathway at a rate greater than what 
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is required for pyruvate oxidation which leads to increased pyruvate generation 
[24]. Additionally, cancer cells also express an alternative isoform of pyruvate 
kinase (PKM2) which is less efficient and causes an accumulation of glycolytic 
intermediates. This, in turn, increases flux into the glycolytic branching pathways 
[24,27,28].  
One of those glycolytic branching pathways leads to the de novo synthesis 
of serine. There are several different metabolic fates of serine that aid in cell 
survival and proliferation including carbon support for production of cysteine, 
phospholipid head groups, sphingosine, glycine, glutathione, and purines [28]. 
Serine can also contribute to redox homeostasis via the reduction of NADPH and 
can feed into one-carbon metabolism to support histone, DNA, and RNA 
methylation as a result of SAM generation [29]. In addition, serine also serves as 
an allosteric activator of PKM, wherein as serine levels increase it promotes PKM2 
into its tetrameric form. This form is more active and drives pyruvate generation. 
Conversely, when serine levels are low, PKM2 is in a dimeric form and causes the 
accumulation of glycolytic intermediates described above [28]. Cells can obtain 
serine through either de novo synthesis or uptake via serine transporters. An 
individual cell’s pool of serine is largely determined by the tissue of origin which 
can determine serine consumption through the expression of the serine 
transporters [30]. While most cancer cells can import serine, there seems to be a 
preference for de novo serine synthesis, so much so that increased activation of 
the serine synthesis pathway (SSP) is now an established component of cancer 
metabolism [29,31]. In addition, the SSP is the metabolic pathway that allows for 
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simultaneous utilization of glucose and glutamine as fuel sources to generate 
serine and intermediates that feed into the TCA cycle. The SSP is a series of three 
reactions that originate from the glycolytic intermediate 3-phophoglycerate and 
accounts for approximately 10% of 3-phosphoglycerate that is metabolized [32]. 
Phosphoglycerate dehydrogenase (PHGDH) is the initiating reaction as it 
catalyzes the conversion of 3-phosphoglycerate to 3-phosphopyruvate [33]. The 
PHGDH reaction in most tissue types is the rate-limiting step and determines the 
overall flux through the pathway. Phosphoserine aminotransferase 1 (PSAT1) 
catalyzes the second step in the serine synthesis pathway through conversion of 
3-phosphohydroxypyruvate to 3-phosphoserine while interconverting glutamate to 
α-ketoglutarate [28]. The last reaction within this pathway is the conversion of 3-
phosphoserine to serine which is catalyzed by the enzyme phosphoserine 
phosphatase (PSPH) [28] (Figure 4). This pathway is utilized differently based on 
tissue type in that some tissues do not express enzymes within this pathway, 
whereas other tissues rely heavily on de novo serine production. 
In the liver, the enzymes within this pathway are expressed at relatively high 
levels compared to other tissue types [34] and are subject to regulation by diet and 
hormone changes [35]. It has been shown that the expression levels of PHGDH 
and PSPH can be directly regulated based on the protein and carbohydrate intake 
ratios in the diet [35]. Another difference in normal liver is that this pathway is not 
regulated by the activity of PHGDH. Flux through the SSP in the liver is determined 
by the activity of PSPH and is driven completely by the cellular need for serine 
[35].  
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Figure 4: Schematic of the Serine Synthesis Pathway. This schematic 
illustrates the three-step serine synthesis pathway and its involvement in 
downstream processes.  This pathway is catalyzed by the enzymes 
phosphoglycerate dehydrogenase (PHGDH), phosphoserine aminotransferase 
1 (PSAT1), and phosphoserine phosphatase (PSPH). 
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The SSP in the brain also differs from most other tissue types. In the brain, 
there is a reliance upon de novo serine synthesis as serine is known to have low 
permeability across the blood-brain barrier [36] and thus the proteins within this 
pathway are greatly expressed within this tissue type [34,36]. This is especially 
true during development. Patients that harbor mutations that decrease the activity 
of any of the serine synthesis enzymes present with neurological disorders [36].  
This has been observed for all three enzymes and the extent of the neurological 
deficit’s correlates to how much enzyme activity has been maintained. Mutations 
in PHGDH have been found in numerous patients and result in severe neurological 
issues [36]. Patients have also presented with mutations in PSAT1, which reduced 
activity to 15%, and these patients also had severe neurological impairments [37].  
As mentioned previously, increased flux through the SSP and increased 
expression of the SSP enzymes have been correlated with tumorigeneses in 
numerous cancer types [29]. The concept that serine biosynthesis and cancer are 
linked is not new. This was first introduced in the 1970s where it was found that 
there was increased growth in rat hepatoma cell lines that had higher PHGDH 
activity [38]. This was followed by work in the 1980s that found flux through the 
SSP was elevated and that this increase correlated with increased tumor growth 
[39]. In the years since these original findings, SSP enzymes have been 
established as crucial enzymes that are necessary for tumorigenesis in several 
different cancer types [29] and have been linked to therapy resistance and 
metastasis [28].  
Much of this work has focused on the rate-limiting enzyme, PHGDH, as this 
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would establish a metabolic requirement for general SSP function. However, there 
is evidence to support alternative roles for other enzymes within this pathway. 
Therefore, the rest of this dissertation will mainly focus on the relevance of the 
enzyme PSAT1. PSAT1 was first molecularly characterized in 2003 [40]. There 
are two different isoforms of PSAT1, PSAT1α and PSAT1β, that can be formed via 
alternative splicing [40]. Although there are two isoforms, only one, PSAT1β, is 
presumed to be physiologically functional as it exhibits a greater level of 
expression compared to the α isoform [40]. The expression of PSAT1 depends on 
tissue type and cell cycle phase. PSAT1 is highly expressed in the brain, liver, 
kidney and pancreas and reaches maximum expression levels during S-phase 
[40]. As mentioned earlier, PSAT1 can also convert glutamate to α-ketoglutarate. 
This gives PSAT1 a role in embryonic stem cell differentiation via control of α-
ketoglutarate levels [41] as it is estimated that PSAT1 accounts for 50% of the 
anaplerotic flux into the TCA cycle [27]. There has also been a substantial amount 
of evidence to support a role for PSAT1 specifically in cancer.  
PSAT1 has been shown to be more active in neoplastic and proliferating 
tissues when compared to normal tissues [42]. This is due to lack of PSAT1 
expression in many normal tissue types including lung, colorectal, ovarian and 
mammary tissues [34]. However, in tumors originating from these tissues 
expression of PSAT1 is greatly increased [43]. This upregulation of PSAT1 in these 
neoplastic cells has been linked to several different mechanisms, including 
epigenetic, miRNA, and transcriptional control.  
Epigenetic regulation of PSAT1 has been shown to be a mechanism for 
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increased serine synthesis. One epigenetic mechanism is reliant upon the 
interaction between menin and MLL1 which, when activated, maintains expression 
of the SSP enzymes in order to support proliferation, cell viability and tumor growth 
in Ewing Sarcoma [44]. Another epigenetic mechanism involves methylation at 
H3K9. In this context, euchromatic histone lysine methlytransferase 2 (G9A) adds 
an activating monomethylating mark, H3K9me1, in order to drive transcription [45]. 
Conversely, KDM4C removes the repressive modification of H3K9me3 which 
allows the transcription of this SSP enzyme [46]. Transcription following this 
epigenetic activation also requires activating transcription factor 4 (ATF4) [46].  
This transcription factor has been shown to regulate PSAT1 in several 
different cancer types. In lung cancer, ATF4, under control of NRF2, regulates SSP 
enzyme expression in order to support glutathione and nucleotide production [47]. 
Also in lung cancer, ATF4 tethers MDM2 to the chromatin in order to drive 
activation of serine synthesis in order to support amino acid metabolism and redox 
homeostasis [48]. Lastly, ATF4 has been shown to regulate expression of PSAT1 
in breast cancer to promote cell cycle progression [49].  
There are also proteins other than ATF4 that have been implicated in 
regulating the serine synthesis pathway. The entire pathway is regulated by p73 
via glutaminase 2 (GLS-2) in lung cancer as a result of a need for converting 
glutamine into glutamate [50]. In Ewing Sarcoma, EWS-FLI1 drives SSP 
expression while increasing the uptake of glutamine in order to maintain redox 
homeostasis [51]. Along the same idea, SSP enzyme expression has been shown 
to be upregulated in response to different stress signals found in the tumor 
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microenvironment. In liver cancer, glucose and glutamine deprivation resulted in a 
C-MYC-dependent increase in the enzymes of the SSP to support glutathione 
production, cell cycle progression, and nucleic acid synthesis [52]. Arginine 
deprivation was also shown to cause an upregulation in the SSP enzymes [53]. It 
has also been shown that serine deprivation causes an increase in the expression 
of the SSP enzymes to support cell survival by providing serine to maintain 
proliferation and mammalian target of rapamycin complex 1 (mTORC1) activity 
[54]. The SSP enzymes, including PSAT1, have also been shown to be induced 
by hypoxic conditions found in the tumor microenvironment [55]. 
PSAT1 can also be regulated independently from the other enzymes in 
serine synthesis pathway. PSAT1 has been shown to be a direct target of miR-
340, miR-365, and miR-424 [56-58]. This regulation occurs in both esophageal 
(miR-340 and miR-365) and colorectal cancer (miR-424). In every instance, the 
miRNA was acting as a tumor suppressor and loss of the miRNA resulted in an 
increase in PSAT1 expression and a subsequent increase in the tumorigenic 
properties of those cancer types [56-58].  
Besides miRNA regulation, there are several other mechanisms implicated 
in the specific regulation of PSAT. In lung cancer, PSAT1 expression is controlled 
by the deactivation of NF1. The subsequent activation of FAK1 results in a 
glutamate dependence that is reliant upon PSAT1 [59]. In breast cancer two 
different means of regulation have been suggested for PSAT1. One proposed 
mechanism is through the transcription factors TAZ/YAP [60]. In this scenario 
TAZ/YAP induce PSAT1 expression to mediate a growth dependence on 
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exogenous glutamine [60] and this is primarily observed in high grade TNBCs 
[60,61]. The other proposed mechanism in breast cancer is regulation by the 
PI3K/Akt/mTOR pathway [62]. Control of PSAT1 in this pathway was achieved via 
a reduction of mRNA and protein levels of PSAT1 following mTOR inhibition and 
MyrAkt induction was able to attenuate this reduction in expression [62]. It was 
also determined that the regulation of PSAT1 by the PI3K/Akt/mTOR pathway was 
independent of proliferation [62]. Induction of expression of PSAT1 by mTORC1 
was also observed in pancreatic cancer, but in that context, it seemed to be a 
means of SSP regulation and not PSAT1 specifically [63]. These various 
mechanisms utilized for the regulation of PSAT1 demonstrate a need for the 
expression of this protein in cancer cells and suggests that PSAT1 plays a crucial 
role in malignant disease. 
 As noted, PSAT1 has been demonstrated to have increased expression in 
several types of cancer. This upregulated expression appears to be directly related 
to survival in most of these cancer types. Its expression has been correlated with 
increased proliferation, resistance to therapy, metastasis, and poorer patient 
outcomes. The following section will focus on what role, if known, PSAT1 plays in 
various cancer types and if these roles are related to the SSP or an independent 
function of PSAT1.  
PSAT1 in Thyroid Cancer 
 In thyroid cancer, the serine synthesis pathway is activated and requires 
PSAT1 activity. It was found that the expression levels of the SSP enzymes could 
determine the subtype of thyroid cancer, as the SSP enzymes had higher 
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expression in the poorly differentiated carcinoma (PDC) and papillary thyroid 
carcinoma (PTC). Yet, they had very low expression in the medullary carcinoma 
(MC) subtype [64]. This group also found that a BRAF mutation (V600E) 
associated with PSAT1 expression. Patients with this BRAF mutation had higher 
expression of the SSP enzymes compared to patients with wild-type BRAF [64]. 
PSAT1 in Nasopharyngeal Carcinoma 
 In nasopharyngeal carcinoma, PSAT1 was identified as a potential 
biomarker for prognosis [65]. In this cancer type, high PSAT1 expression 
associated with an aggressive clinical course and advanced tumor stage. In 
addition, it correlated with reduced disease-specific survival, distant-metastatic-
free survival, local-recurrence-free survival, overall survival, and was an overall 
indicator of poorer patient prognosis [65]. 
PSAT1 in Melanoma 
 The effects of PSAT1 in melanoma are directly related to its function 
regarding serine biosynthesis. Melanoma has one of the highest frequencies of 
PHGDH amplifications compared to other cancer types [66]. This amplification of 
PHGDH, along with increased expression of the other SSP enzymes, results in 
increased flux through the serine biosynthetic pathway [67]. Cells that harbor these 
PHGDH amplifications are sensitive to PHGDH, or other SSP enzyme, 
suppression where silencing leads to a reduction in cell proliferation [67]. These 
SSP enzymes, including PSAT1, have also been identified as necessary for the 
observed resistance to BRAF inhibitors in this cancer type [68].    
PSAT1 in Pancreatic Cancer 
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 The role of PSAT1 in pancreatic cancer is also related to its function in the 
serine synthesis pathway. The SSP enzymes in pancreatic cancer can be induced 
by mTOR [63]. This overexpression is required for further down-stream one-carbon 
metabolism that supplies the s-adenosylmethionine levels in order to meet the 
methylation needs of the cell [63]. The overexpression of PSAT1 is also required 
for tumorigenesis of pancreatic cancer, especially under the conditions of liver 
kinase B1 (LKB1) loss. Upon loss of LKB1, PSAT1 is required for proliferation, 
colony formation, and subcutaneous tumor growth [63]. SSP enzymes have also 
been identified as necessary components of BRAF inhibitor resistance [68]. In 
resistant cell types, the BRAF inhibitor vemurafenib induced the expression of the 
SSP enzymes and resulted in an increase in cell proliferation [68]. 
PSAT1 in Multiple Myeloma 
 The expression of PSAT1, and other serine synthesis enzymes, in multiple 
myeloma has been directly associated with resistance to therapeutic treatment 
[69]. It was observed that all SSP enzymes had higher expression in cell types that 
were determined to be resistant to bortezomib [69]. This correlation was so 
significant that it was determined that SSP enzyme expression could potentially be 
used as a biomarker to identify patients that would be resistant to this therapeutic 
option [69]. 
PSAT1 in Hepatocellular Carcinoma 
 The role of PSAT1 in normal liver differs from other tissues and this also 
extends to tumors originating from this tissue type. In hepatocellular carcinoma, 
PSPH, the rate-limiting enzyme in the liver, is significantly upregulated compared 
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to normal liver expression while PHGDH and PSAT1 are downregulated [70]. It is 
suggested that these expressions patterns are due to a developed reliance on 
glutamine within the tumor in order to fuel the TCA cycle [70]. 
PSAT1 in Glioblastoma  
With the dependence in the brain on de novo serine synthesis, these 
proteins are normally expressed at higher levels than other tissues [34]. In 
glioblastoma, there is a reduction in the expression of PSAT1 in tumors compared 
to normal tissue and this reduction in expression is exacerbated in higher grade 
tumors compared to lower grade tumors [71]. It was also determined that certain 
therapies, i.e. Regorafenib, require high PSAT1 expression in order to suppress 
tumor growth in glioblastoma multiforme [71]. 
PSAT1 in Ewing Sarcoma 
 In Ewing sarcoma, the entire serine synthesis pathway is highly active, and 
these enzymes (PHGDH, PSAT1, and PSPH) are essential for proliferation, 
viability, and tumor growth [44]. This pathway has also been associated with 
regulation of redox homeostasis and protecting these tumors against DNA damage 
and apoptosis [51]. The expression of the SSP enzymes are also an indicator of 
prognosis within this cancer type. Patients with higher expression are classified as 
a high-risk group with poorer overall survival [51]. 
PSAT1 in Esophageal Squamous Cell Carcinoma 
 PSAT1 expression is elevated in esophageal squamous cell carcinoma 
compared to normal tissue [72]. Characteristically, elevated PSAT1 expression 
contributes to proliferation, epithelial to mesenchymal transition, invasion, and 
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progression [57,58,72]. Higher expression of PSAT1 also enhanced tumor 
formation in vivo [72]. Functionally, it is suggested that PSAT1 is contributing to 
these tumorigenic processes via a promotion of GSK3β/snail activity [72]. 
Clinically, increased expression of PSAT1 has been correlated with stage of 
disease, lymph node metastasis, distant metastasis, and overall poorer patient 
prognosis [72]. 
PSAT1 in Colon Cancer 
 PSAT1 is highly expressed in colon tumor tissue compared to normal colon 
[73,74] and has even been identified as the most upregulated gene in colorectal 
carcinoma [75]. Increased PSAT1 expression in colon cancer has been shown to 
have an integral role in tumor growth both in vitro and in vivo as well as evasion of 
apoptosis [56]. Clinically, higher levels of PSAT1 expression has been associated 
with chemo-resistance [73,75]. Increased PSAT1 expression correlates with a 
reduced sensitivity to oxaliplatin [73] as well as resistance to irinotecan, 5-
fluorouracil, and leucovorin therapy and a resulting decrease in patient survival 
time [75]. This finding has led to the suggestion that PSAT1 be used as a biomarker 
for resistant colorectal carcinoma [75]. Mechanistically, it seems that PSAT1 is 
contributing to an increased growth rate and chemo-resistance via a canonical 
function in serine-synthesis and downstream one-carbon metabolism [76]. 
PSAT1 in Ovarian Cancer 
 In ovarian cancer, PSAT1 expression is increased in tumor tissue compared 
to adjacent normal tissue [77-79]. This overexpression can be used as a biomarker 
to sort into different molecular categories as PSAT1 was observed to be strongly 
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expressed in the ovarian clear cell carcinoma subtype [78]. It has also been found 
that PSAT1 expression levels correlate to clinical stage and tissue differentiation 
[79]. Elevated PSAT1 expression contributes to disease occurrence, development, 
and prognosis [79] via a promotion of GSK3β phosphorylation, angiogenesis, and 
enhanced expression of HIF-1α, VEGF, and β-catenin [77]. In addition, elevated 
PSAT1 expression in ovarian cancer has been linked to resistance to cisplatin 
treatment [77]. 
PSAT1 in Lung Cancer 
 In lung cancer there is evidence for both SSP and independent roles of 
PSAT1. The function of PSAT1 in lung cancer that is related to serine biosynthesis 
is driven by a need for flux through the pathway in order to generate serine. This 
supports cell proliferation and mTORC1 activity during times of serine deprivation 
[54]. This also occurs as a response to oxidative stress [50] as a means to regulate 
redox homeostasis during these conditions [48]. Reliance upon the SSP has also 
been defined as a specific molecular subtype in lung adenocarcinoma. The 
enzymes in the SSP are upregulated in this pathway in order to maintain flux 
through the serine pathway and correlates with significantly poorer patient 
prognosis [80]. In addition, PSAT1 was found to be significantly upregulated in 
non-small cell lung cancer [81]. This increase contributed to cell cycle progression, 
cell proliferation, tumorigenesis, and was involved in the regulation of the Rb-E2F 
pathway activity by inhibition of cyclin D1 degradation [81]. This suggests that 
PSAT1 may have a function outside of its enzymatic activity in contributing to 
generation of serine. In addition, clinically overexpressed PSAT1 conferred a 
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poorer clinical outcome for patients [81] PSAT1 was also identified as mediating a 
glutamine dependence in a subset of Kras driven lung adenocarcinomas that 
harbor a loss of function mutation in NF1 via a FAK1-dependent mechanism [59]. 
PSAT1 in Breast Cancer 
A connection between PSAT1 expression and breast cancer was first 
described in 2005 by Martens et al. They found that the extent of methylation on 
the PSAT1 promoter, and thus PSAT1 mRNA expression, was indicative of a 
response to tamoxifen therapy in ER+BC with recurrent disease [82]. Since then, 
there has been an increase in the investigation into the role of the serine synthesis 
pathway and PSAT1 in the development, progression, and treatment of breast 
cancer. Most of this work has looked at PSAT1 in the context of its canonical 
function within the serine synthesis pathway.  
It has been determined that serine synthesis pathway enzyme expression 
levels in breast cancer could predict patient survival [83]. The enzymes in the SSP 
were upregulated in a metastatic variant of TNBC breast cancer and that this 
increase was correlated with decreased relapse-free and overall survival of 
patients with TNBC [84]. It was also noted in these studies that increased serine 
biosynthesis promoted bone metastasis via the stimulatory effect of serine on 
osteoclastogenesis [84] and that PSAT1 expression specifically was required for 
this development [85]. Certain breast cancers exhibit a dependence on flux 
through the serine synthesis pathway, driven by a dependence on PHGDH as the 
rate-limiting enzyme. In these subsets, SSP enzyme expression is required for 
tumorigenesis and correlates with aggressiveness of disease [86-88]. This 
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requirement for flux through the SSP, also termed serine synthesis-dependence, 
makes these cells sensitive to manipulation in SSP enzyme expression wherein 
either genetic reduction or pharmaceutical inhibition causes a significant 
proliferative defect in these cell types [86,87,89]. As was mentioned earlier, 
hypoxia can induce expression of the SSP enzymes. This hypoxic induction of the 
SSP enzymes allows for the maintenance of redox homeostasis as serine 
synthesis reactions generate NADPH [90]. This causes an enrichment in breast 
cancer stem cells and indicates a role for this pathway in the evasion of cell death 
from chemotherapy treatment and in the formation of secondary tumor sites 
[55,91]. The increased expression of the SSP enzymes are not restricted to tumor 
cells. It has also been showed that there is an increase in SSP enzymes in stromal 
tissue that correlates with an increase in histological grade of breast phyllode 
tumors [92]. In addition, there is evidence to support that depending on the 
origination of the disease, i.e. ductal or lobular, expression of the SSP enzymes 
will be higher in either the tumor cells (invasive lobular carcinoma) or stromal tissue 
(invasive ductal carcinoma) [93]. 
Outside of the serine synthesis pathway in general, there has been 
investigation into the role of PSAT1 in breast cancer. PSAT1 was shown to have 
higher expression in estrogen receptor negative cancers compared to estrogen 
receptor positive cancers due to a loss of promoter methylation [94]. In addition to 
ER status, PSAT1 promoter methylation (i.e. lack of PSAT1 expression) correlated 
with low-grade, low-proliferation, lymph node positive BC in women who were post-
menopausal and Caucasian [95]. Low promoter methylation of PSAT1 (i.e. high 
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PSAT1 expression) was associated with higher tumor grade, pN stage, and poorer 
disease-free survival in patients [96]. As mentioned earlier, PSAT1 mRNA levels 
were able to be a predictor of response to tamoxifen treatment [82]. That work was 
further expounded upon and demonstrated that protein levels of PSAT1 were also 
associated with poorer patient outcome upon tamoxifen treatment [97]. Further, 
high PSAT1 expression has been correlated to poorer overall survival, recurrence 
free survival, and identified as part of a gene signature inclusive of all breast cancer 
subtypes [98]. 
While it is evident that there is an increase in the expression of PSAT1 in 
several cancer types and that increased PSAT1 generally associates with clinical 
outcomes, I will be focusing the rest of this dissertation on the role(s) of PSAT1 in 
breast cancer.  It is known that PSAT1 is increased in breast cancers and that this 
increase correlates with poorer survival for patients; however, the requirement of 
PSAT1 in different subtypes of breast cancer is still poorly understood in the 
progression of this disease. While there is a clear indication that there is a role for 
PSAT1’s function within the serine synthesis pathway in breast cancers that are 
serine synthesis-dependent, this only accounts for a limited subset of breast 
cancers. In cancers that are classified as independent of serine synthesis, yet still 
express elevated levels of PSAT1, it is unclear what function or role increased 
PSAT1 provides the tumor in this context. The majority of this doctoral work has 
been completed in the context of TNBC as the expression of PSAT1 is greater in 
this molecular subtype even in those TNBCs designated as serine synthesis 
independent. However, PSAT1 has also been reported to be expressed in ER+BC, 
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especially in tumors that are resistant to endocrine therapy. To date, there is no 
indication of whether this therapy induced increase in expression promotes either 
elevated flux through the serine pathway or a non-canonical function of PSAT1 
that contributes to acquired resistance.  
These gaps in knowledge are the basis for this dissertation. The role of 
PSAT1 in a serine synthesis-independent system will be examined in TNBC. The 
rationale for investigation in this molecular subtype is that while a large portion of 
TNBCs (70%) upregulate the serine biosynthetic enzymes, only 6% of that 70% 
are due to genetic amplification of PHGDH [87]. These statistics suggest that there 
is a large subset that may upregulate PSAT1 independently of other SSP enzymes 
and thus the function for this increase is unknown. Due to the metastatic nature of 
TNBCs, the variable independent increases observed in PSAT1, PSAT1’s 
correlation with higher grade TNBCs, and the association between higher grade 
tumors and metastasis, we speculate that PSAT1 may be involved in the 
metastatic potential of TNBC (Aim 1) and this function of PSAT1 is unrelated to its 
function in serine biosynthesis (Aim 3). 
The other aim (Aim 2) of this dissertation is to further investigate a finding 
by Martens et al. High expression of PSAT1 was demonstrated as the strongest 
negative correlation with response to endocrine therapies in a study on patients 
with recurrent ER+ breast cancer [82]. In a follow-up study these results were 
confirmed at the protein level and in a second patient cohort [97]. This second 
study suggests that the contribution of PSAT1 to resistance may rely on flux 
through the serine synthesis pathway as increases in PHGDH were also observed. 
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It is my goal to examine the effects of altered PSAT1 expression on the sensitivity 
to endocrine therapy in both endocrine sensitive and resistant ER+BC. In addition, 
we will examine whether these suggested functions of PSAT1 are the result of its 
involvement in the serine biosynthetic pathway. 
The elevated expression of PSAT1 in breast cancer compared to normal 
mammary tissue, combined with previously published data and our own results 
suggests that PSAT1 contributes to breast cancer progression by promoting TNBC 
metastasis in a serine-independent context and endocrine resistance in ER+BC 
possibly through a requirement for serine synthesis. I have devised three aims to 
evaluate this hypothesis. 
1. Determine the effect of PSAT1 suppression in breast cancer 
metastasis in vitro and in vivo. This aim will be evaluated in a specific 
subset of TNBC that is “serine synthesis-independent” and will implement 
several in vitro assays of metastatic characteristics. 
2. Determine the effect of PSAT1 expression on endocrine resistance 
within ER+BC. This aim will be evaluated in both ER+ endocrine sensitive 
and endocrine resistant cell lines and determine if suppression of PSAT1 
affects sensitivity to endocrine therapies. 
3. Determine if there is a requirement for serine synthesis and thus 
PSAT1 in breast cancer progression. The requirement for serine 
synthesis will be evaluated in our TNBC model system and employ both the 
suppression of PSAT1 as well as the suppression of the rate-limiting 
enzyme PHGDH.
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CHAPTER 2 
SELECTIVE LOSS OF PHOSPHOSERINE AMINOTRANSFERASE 1 (PSAT1) 
SUPPRESSES TRIPLE NEGATIVE BREAST CANCER METASTASIS 
Introduction 
Breast cancer is the most prevalent cancer diagnosis and the second 
leading cause of cancer-related deaths among women. Metastatic disease is 
responsible for over 90% of breast cancer related mortalities [15], which 
culminates in an overall survival rate of 22% for metastatic patients [2]. Metastasis 
or advanced recurrent disease affects approximately 30% of patients and is 
clinically challenging as therapies are often directed at prolonging survival without 
compromising quality of life [14]. Metastasis can arise from all breast cancer 
subtypes [17] but triple negative breast cancer (TNBC) is considered the most 
aggressive as it correlates with poorer overall survival in both early stage and 
metastatic disease [4]. Separate from hormone receptor positive breast cancers, 
TNBC is characterized by the lack of estrogen receptor-α (ERα), progesterone 
receptor (PR), and human epidermal growth factor receptor 2 (HER2) expression 
[4].  
Despite the inherent heterogeneity of TNBC tumors, 70% of TNBCs 
upregulate the expression of enzymes within the serine synthesis pathway (SSP) 
[87]. The SSP is a glycolytic shunt that is responsible for converting 3-
31 
 
phosphoglycerate into serine through a series of three reactions. The first reaction, 
and rate-limiting step, is catalyzed by phosphoglycerate dehydrogenase (PHGDH) 
and converts 3-phosphoglycerate into 3-phosphohydroxypyruvate. The second 
enzyme, phosphoserine aminotransferase (PSAT1), couples the conversion of 
glutamate to α-ketoglutarate with the production of 3-phosphoserine. 
Phosphoserine phosphatase (PSPH) then dephosphorylates 3-phosphoserine into 
serine. Most of the previous work involving the SSP and TNBC has focused on a 
role for PHGDH. Select primary TNBCs and TNBC cell lines have been previously 
designated as “serine-dependent” or reliant on the cellular production of serine. 
These cells harbor genetic amplifications of PHGDH or have extremely high 
PHGDH expression, within which PHGDH silencing causes a significant decrease 
in proliferation due to loss of alpha-ketoglutarate production through PSAT1 [87]. 
However, these gene amplifications of PHGDH only account for 6% of primary 
tumors and 18% of breast cancer cell lines [87]. “Serine synthesis-independent” 
TNBC cell lines do not harbor genetic amplifications of PHGDH and loss of SSP 
enzymes yields no anti-proliferative effect in the presence of exogenous serine. 
Yet, many of these cell types demonstrate elevated expression of the SSP 
enzymes compared to normal breast tissue, particularly PSAT1, suggesting that 
these enzymes may have additional functions in TNBC progression [55,87]. 
While PSAT1 is not expressed in normal mammary tissue [34], it is elevated 
in several breast cancer subtypes as well as in several other aggressive 
malignancies including colon cancer, nasopharyngeal carcinoma, human 
esophageal squamous cell carcinoma, and non-small cell lung cancer 
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[49,55,65,72,73,81]. Control of PSAT1 expression is driven by several oncogenic 
pathways and is differently regulated throughout cell-cycle progression 
[42,44,47,49,50,52,60]. Increased PSAT1 expression has been correlated with 
multiple tumorigenic characteristics, including metastasis and chemoresistance, 
and is correlated with poorer patient prognosis [49,72,73,81,84].  
Based on previous reports detailing the requirement for SSP enzymes in 
“serine synthesis-dependent” TNBC proliferation coupled with PSAT1’s elevated 
expression in “serine synthesis-independent” TNBC cells, we examined PSAT1’s 
potential contribution to other TNBC features, particularly in metastatic potential. 
In this report, we demonstrate that PSAT1 expression increases with TNBC grade 
and that selective suppression of PSAT1 inhibits metastatic characteristics both in 
vitro and in vivo without affecting proliferation. Importantly, loss of PHGDH in 
“serine synthesis-independent” cells did not phenocopy PSAT1 silencing, 
suggesting that these effects are specific to PSAT1 in these cell types. Together, 
these data indicate that PSAT1 plays a role in metastatic potential in TNBC. 
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Methods and Materials 
Immunohistochemistry 
 PSAT1 expression was determined in a panel of commercially available 
tissue microarrays (TMA) that contained de-identified TNBC tumor core sections 
with provided clinical characteristics, such as grade and histological status of the 
estrogen and progesterone receptors and HER2 (US Biomax, BR487, BR243, 
BR1503, and BR1504). TMAs were dewaxed and rehydrated using a series of 
xylene and ethanol washes. Tissues were then blocked with 5% goat serum and 
incubated with 1:100 dilution of anti-PSAT1 antibody (ProteinTech) for 16 hours at 
4°. Sections were subsequently incubated with 1:1000-fold dilution of HRP-
conjugated anti-rabbit antibody. PSAT1 was detected using DAB stain (Vector 
Laboratories), counterstained with hematoxylin, and image was digitally captured 
using AperioScope digital slide scanner. 
 Analysis of PSAT1 staining in TNBC sections (ER-, PR-, and HER2- 
staining as defined by the provided histological reports with each TMA) was 
performed using Aperio ImageScope software with the positive pixel count 
algorithm. Areas of analysis excluded stromal tissue in the tumor samples and was 
defined to ductal epithelial in the normal breast tissue sections. Comparison of 
relative PSAT1 levels between normal, grade 1, grade 2, and grade3 TNBC tissues 
was determined by dividing the positive pixel count by total pixels (sum of positive 
and negative) as determined by the software.   
Cell Culture 
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The MDA-MB-231 and HCC1806 TNBC cell lines were obtained from 
ATCC. MDA-MB-231 cells were cultured in IMEM supplemented with 5% FBS and 
gentamicin and HCC1806 cells were cultured in RPMI-1640 medium 
supplemented with 10% FBS and gentamicin. HEK 293T cells were also obtained 
from ATCC and cultured in DMEM supplemented with 10% FBS and gentamicin. 
All cells were incubated at 37° in 5% CO2. 
Plasmid Generation 
 The PSAT1 and TIMP2 genes were isolated via the utilization of primers 
targeting the 3’ and 5’ ends of the mature RNA encoding for either PSAT1 or 
TIMP2. These primers were adapted to include the restriction enzymes ECOR1 
and BAMH1. Polymerase chain reactions were performed to amplify the region 
and the products were then separated via gel electrophoresis. The corresponding 
bands were excised from the gel and purified. They were then ligated into either a 
FLAG-tagged vector (PSAT1) or a GFP-tagged vector (TIMP2), transformed into 
bacterial strains, and plated on LB agar with ampicillin. A single bacterial colony 
was then cultured in LB broth and ampicillin for 24 hours and plasmids were 
isolated from the culture via the Qiagen Miniprep kits and confirmed by 
sequencing. 
Transfections 
 PSAT1 siRNA and scrambled negative control siRNA were purchased from 
Ambion. PHGDH siRNA and non-targeting control pool siRNA were purchased 
from Dharmacon. PSAT1 shRNA, PHGDH shRNA, and Control shRNA were 
purchased from Sigma. The FLAG-PSAT1 and GFP-TIMP2 were generated as 
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described above. For overexpression, FLAG-PSAT1, GFP-TIMP2, and the empty 
vectors were transfected into HEK 293 cells using the Polyplus jetPRIME reagent. 
For transient suppression, siRNAs were transfected into either MDA-MB-231 or 
HCC1806 cells using RNAiMax Lipofectamine or Polyplus INTERFERin systems 
according to manufacturer’s protocol. For stable suppression cell line generation, 
shRNAs were transfected into cells using the Polyplus jetPRIME reagent according 
to manufacturer’s protocol and clonal selection for gene silencing was performed 
using puromycin. The sequences for all siRNA and shRNA species are as follows: 
PSAT1 RNAi: 5’-CCCUAAACUUGGGAGUUAUtt-3’, negative control RNAi: 
Silencer Select Negative Control No. 2 cat#4390846, PHGDH RNAi: 5’-
CGACAGGUUGCUGAAUGA-3’, non-targeting pool RNAis: 5’-
UGGUUUACAUGUCGACUAA-3’, 5’-UGGUUUACAUGUUGUGUA-3’, 5’-
UGGUUUACAUGUUUUCUGA-3’, 5’-UGGUUUACAUGUUUUCCUA-3’, PSAT1 
shRNA: 5’-
CCGGGCACTCAGTGTTGTTAGAGATCTCGAGATCTCTAACAACACTGAGTG
CTTTTTG-3’, PHGDH shRNA: 5’- 
CCGGCTTCGATGAAGGACGGCAAATCTCGAGATTTGCCGTCCTTCATCGAA
GTTTTTG-3’, Control shRNA: 5’- 
CCGGCAACAAGATGAAGAGCACCAACTCGAGTTGGTGCTCTTCATCTTGTT
GTTTTT-3’. 
Immunoblot Assays 
 Whole-cell lysates were prepared in IP Lysis Buffer (Pierce) containing 
protease and phosphatase inhibitors. Proteins were separated on 10% SDS-
36 
 
polyacrylamide gels and transferred to PVDF. Membranes were blocked with 5% 
non-fat dry milk in TBS-T and subsequently probed with 1:1000-fold dilution of anti-
PSAT1 (Proteintech, 10501-1-AP) or anti-PHGDH (Sigma HPA021241) antibodies 
for 16 hours at 4°. Washed membranes were then incubated with 1:5000 dilution 
of HRP-conjugated anti-rabbit or anti-mouse secondary antibodies. Protein 
detection was done by exposure to ECL Prime chemiluminescent reagent (GE 
Healthcare). Protein loading was assessed using anti-β-actin antibody (Sigma, 
A2228). 
Cell Proliferation  
 For shRNA silencing, MDA-MB-231 (50,000) cells with or without stable 
knock-down of PSAT1 or PHGHD were seeded in triplicate in a 12-well (Corning) 
plate. Cell proliferation was assessed by counting of trypan blue excluded cells 24 
and 48-hours post-seeding. For siRNA suppression, MDA-MB-231 (50,000) or 
HCC1806 (30,000) were seeded in 12-well or 24-well (Corning) plate respectively, 
24-hours post-transfection. Cells were then counted via trypan blue exclusion 24 
or 48-hours post-seeding.  
Wound Healing Assay 
MDA-MB-231 or HCC1806 cells were seeded at 200,000 cells per well in a 
12-well (Corning) plate. Cells were either seeded directly (stable shRNA 
suppression) or 24-hours post siRNA transfection. Scratch in the confluent 
monolayer was generated with a sterile 200μL pipette tip. Images were taken at 
0HR and 24HR time intervals and % wound healing was quantified using ImageJ. 
Migration and Invasion Assays 
37 
 
For migration assays, MDA-MB-231 and HCC1806 cells were serum 
starved for 24 hours and then plated (25,000 and 50,000 respectively) into Boyden 
chambers in serum-free medium. Serum-containing medium was placed in each 
well to serve as the chemoattractant. At 24 hours, inserts were fixed with 100% 
methanol for 10 minutes and non-migrated cell were removed with a cotton swab. 
The inserts were then washed with PBS and stained with crystal violet. Images 
were captured via an EVOS microscope and multiple 4X fields were analyzed with 
ImageJ. 
For invasion assays, MDA-MB-231 cells were serum starved for a period of 
24 hours and then plated (50,000) into Corning Biocoat Matrigel Invasion 
Chambers (Corning) following rehydration according to manufacturer’s protocol. 
The cells were allowed to invade for 24 hours at which point the inserts were fixed 
with 100% methanol for 10 minutes and non-invasive cells and remaining matrigel 
layer were removed via cotton swab. The inserts were then washed with PBS and 
stained with crystal violet. Images were captured via an EVOS microscope and 
multiple 4X fields were analyzed with ImageJ. 
Quantitative-Real Time Polymerase-Chain Reaction 
 MDA-MB-231 or HCC1806 cells were collected and total RNA was isolated 
using the RNeasy Mini Kit (Qiagen). One milligram of RNA was converted to cDNA 
using the High-Capacity RNA-to-cDNA kit (appliedbiosystems) according to the 
manufacture’s protocol. Samples were then analyzed for qPCR via the TaqMan 
Fast Advanced (appliedbiosystems) system with human probes for PSAT1 
(Hs00795278_mH), PHGDH (Hs00198333_m1), and ACTB (Hs01060665_g1). 
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Anchorage-Independent Growth 
 A bottom layer of 0.6% noble agar in complete medium was prepared in six-
centimeter dishes. MDA-MB-231 cells were seeded at 50,000 cells per dish in a 
0.3% agar solution. Cell colonies were refreshed with 0.25% agar/medium solution 
every 3-5 days during the 21-day assay. Images were captured via a Nikon digital 
camera (DXM1200F) attached to a Nikon (SMZ1500) microscope. 
Actin Cytoskeleton Staining 
 MDA-MB-231 (30,000) or HCC1806 (60,000) cells were plated in Lab-Tek 
II Chamber slides (154526) either directly or following transfection with siRNA 
species. Forty-eight hours after plating, cells were fixed with 3.7% formaldehyde 
solution. The cells were then permeabilized with 0.1% Triton X-100 in PBS before 
staining with phalloidin (Thermo Fisher) and DAPI (Thermo Fisher) following 
manufacturer’s protocol. Cellular staining was visualized using an Olympus FV-
3000 confocal microscope equipped with Flouview software (Olympus America 
Inc.) under 40X magnification. 
Animal Model for Experimental Metastasis 
The in vivo study was approved by the University of Louisville’s Institutional 
Animal Care and Use Committee. The experimental in vivo metastasis model was 
performed as previously established for MDA-MB-231 cells [99]. Briefly, MDA-MB-
231 cells with or without PSAT1 silencing were collected, washed, and 
resuspended in PBS at a concentration of 1 x 106/mL. One hundred microliters of 
cell suspension were intravenously injected into the tail vein of athymic nude mice 
(Charles River). Lung tissue was resected 8 weeks post-injection, formalin fixed, 
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and embedded in paraffin. FFPE lung tissue was sectioned and stained with 
hematoxylin and eosin to detect MDA-MB-231 lung lesions. Images were captured 
using AperioScope digital slide scanner and micro-metastatic foci were counted 
from three separate image fields (under 4X magnification) across individual tissue 
sections from each animal. 
Co-Immunoprecipitation 
 HEK 293T cells were transfected with FLAG-PSAT1 and GFP-TIMP2. 
Forty-eight hours post transfection, cell pellets were collected and whole-cell 
lysates were prepared in IP Lysis Buffer (Pierce) containing protease and 
phosphatase inhibitors. Anti-FLAG M2 magnetic beads (Sigma) were prepared 
according to manufactures instructions prior to overnight incubation with 1mg of 
protein lysate. Proteins not bound to the beads were removed by washing prior to 
elution. Remaining proteins were separated on 10% SDS-polyacrylamide gels and 
transferred to PVDF. Membranes were blocked with 5% non-fat dry milk in TBS-T 
and subsequently probed with 1:1000-fold dilution of anti-FLAG (DYKDDDDK) 
(Cell Signaling, 23685), anti-PSAT1 (Proteintech 10501-1-AP), or anti-GFP 
(Sigma G1546) antibodies for 16 hours at 4°. Washed membranes were then 
incubated with 1:5000 dilution of HRP-conjugated anti-rabbit or anti-mouse 
secondary antibodies. Protein detection was done by exposure to ECL Prime 
chemiluminescent reagent (GE Healthcare). 
Statistical Analysis 
 Statistical analysis of all studies was performed with Graph Pad Prism 
software using either analysis of variance or unpaired t test. p values for all results 
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are indicated in their respective figure legends. 
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Results 
PSAT1 expression increases with TNBC grade 
In support of the clinical relevance of the serine synthetic pathway in TNBC, 
we performed immunohistochemistry analysis of breast tissue samples from 
normal tissue, or at varying grades of TNBC. Similar to previous reports [34], we 
found that normal breast tissues express low levels of PSAT1 compared to TNBC 
(Figure 5A). Quantitation of PSAT1 staining revealed a trend towards elevated 
levels in grade 1 tumor tissue that is significantly increased in higher grades within 
these TNBC tissues (Figure 5B). These results demonstrate that PSAT1 is 
expressed in breast tumor tissue, suggesting that PSAT1 has a potential role in 
the progression of TNBC. 
Suppression of PSAT1 inhibits migration and invasion of select TNBC cell 
types without affecting cell proliferation 
Prior studies have established the SSP as a crucial pathway in cancer 
progression, including TNBC [84,87]. However, most of this work has focused on 
a subset of TNBC designated as “serine-synthesis dependent” in which 
suppression of any of the SSP enzymes causes a significant proliferative defect. 
However, there are cell lines in which serine synthesis is dispensable for cell 
proliferation; yet they still upregulate SSP enzymes when compared to normal 
breast tissue [87]. This increased expression of SSP enzymes, namely PSAT1, in 
these serine synthesis-independent cell lines suggests that they may promote 
tumorigenic properties beyond enhanced proliferation. Based on this, we sought 
to determine if there was a metastatic role for PSAT1 in two defined serin 
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Figure 5: PSAT1 expression increases with TNBC grade. A) Formalin-fixed 
paraffin embedded tissue sections were examined by immunohistological 
staining for PSAT1. Shown are two independent representative images (20X) 
from either normal breast tissue or from different grades of TNBC from tissue 
microarray core sections. B) Quantitation of PSAT1 staining demonstrates a 
significant increase in expression in higher TNBC grade. Relative levels of 
PSAT1 was determined from multiple normal (n = 7), grade 1 (n = 11), grade 2 
(n = 14), and grade 3 (n = 14) independent TMA tissue sections. Quantification 
is demonstrated as relative level (positive / total pixel) of PSAT1 expression and 
shown are mean + SEM. * p < 0.01, ** p < 0.005, *** p < 0.0001. 
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synthesis-independent TNBC cell models, MDA-MB-231 and HCC1806 [87]. We 
first found differential expression of PHGDH and PSAT1 in both cell types. While 
MDA-MB-231 cells predominantly expressed PSAT1 compared to low level of 
PHGDH, HCC1806 cells exhibited similar levels of both SSP enzymes (Figure 6). 
Consistent with previous reports [55], we found that loss of PSAT1, via either 
stable shRNA or transient siRNA silencing, did not negatively affect cell 
proliferation (Figure 7A&B, Figure 8A&B). Alteration in cell morphology, in part 
due to changes in actin cytoskeleton rearrangement, can directly influence the 
motile capability of tumor cells. To examine whether loss of PSAT1 affected 
cytoskeleton structure and cell morphology, we performed phalloidin staining to 
visualize the F-actin cytoskeleton structure. Upon suppression of PSAT1, MDA-
MB-231 cells exhibited changes in both F-actin cytoskeleton arrangement and 
overall cell morphology compared to control cells (Figure 7C). In particular, there 
was a reduction in the spindle-shaped morphology normally observed in these 
TNBC cells and a disruption in the actin stress fibers (Figure 7C). These results 
suggest that PSAT1 may be important for maintenance of cell morphology and 
may contribute to other tumorigenic properties in the MDA-MB-231 cells, 
particularly cell motility. To determine the relevance of PSAT1 loss on this cellular 
function, we examined the migratory ability of MDA-MB-231 cells, by both wound 
healing and Boyden chamber transwell assays. Both stable and transient 
suppression of PSAT1 significantly decreased motility of MDA-MB-231 cells by 
>50% in both experimental procedures (Figure 9A&B, Figure 10A&B). We next 
investigated the invasive potential of those cells using the matrigel coated  
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Figure 6: PSAT1 and PHGDH transcript and protein expression in 
MDA-MB-231 and HCC1806 TNBC cell lines. A) Transcript levels of 
PSAT1 and PHGDH was determined by RT-PCR. Data is presented 
as change in CT values between PSAT1 or PHGDH and -actin (mean 
+ SD).  B) Western analysis of PSAT1 and PHGDH expression in both 
the MDA-MB-231 and HCC1806 cell lines.  
45 
 
  
PSAT1 
β-Actin 
shControl shPSAT1 
A B 
MDA-MB-231 
shControl 
shPSAT1 
Phalloidin DAPI MergC 
Figure 7: Loss of PSAT1 does not affect proliferation but alters 
appearance actin-cytoskeleton. A) Western blot analysis of PSAT1 
expression in MDA-MB-231 cells selected for stable expression of control or 
PSAT1-specific shRNA. B) Cell proliferation in control or PSAT1-shRNA MDA-
MB-231 cells. Data are represented as mean + SD of viable cell counts at 24 
and 48 hours. Results were analyzed by 2-way ANOVA, p<0.0001 C) 
Representative images of cytoskeleton F-actin filaments upon phalloidin 
staining in both control and PSAT1 shRNA MDA-MB-231 cells. Note: Control is 
the same in the PHGDH experiments 
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Figure 8: SiRNA suppression of PSAT1 has no proliferative effect. A) 
Representative western blot analysis demonstrating PSAT1 expression in MDA-
MB-231 transfected with control or PSAT1 specific siRNA. B) Cell proliferation 
at 24 and 48 hours after transfection with control or PSAT1 siRNA. Data is 
presented as viable cell counts and shown is mean + SD. Results were 
analyzed by 2-way ANOVA. 
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Figure 9: Loss of PSAT1 suppresses MDA-MB-231 motility and invasion 
in vitro. A) Representative images of wound healing assays for both control 
and PSAT1 silencing in MDA-MB-231 cell lines at 0 and 24 hours. Quantification 
is demonstrated as % wound closure (mean + SD), p<0.0001 as determined by 
one-way ANOVA with Tukey’s comparison test. B) Representative images for 
migration assays for both control and PSAT1 suppressed cells. Quantification 
is presented as area stained and shown are mean + SD, p=0.0079 as 
determined by one-way ANOVA with Tukey’s comparison test. C) 
Representative images of Matrigel invasion assays with both stable shRNA 
MDA-MB-231 cell lines. Quantification is reported as area stained and 
represented as mean + SD, p < 0.0001 as determined by unpaired t test. Note: 
Controls are the same as those represented within the PHGDH experiments. 
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Figure 10: SiRNA suppression of PSAT1 decreases motility of MDA-MB-
231 cells in vitro. A) Representative images of wound healing assays of MDA-
MB-231 cells with transient suppression of PSAT1. Quantification is presented 
as % wound closure (mean + SD), p=0.0217 as determined by unpaired t test. 
B) Boyden chamber migration assays were quantified as mean + SD area 
stained, p=0.0139 as determined by unpaired t test. 
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transwells and found that suppression of PSAT1 also significantly inhibited MDA-
MB-231 cell invasiveness (Figure 9C). 
To determine if these results were unique to these cells or extend to other 
serine synthesis independent cell systems, we examined the effects of PSAT1 
suppression on HCC1806 cells that exhibit comparable PSAT1 and PHGDH 
expression (Figure 6). Similar to the MDA-MB-231 cells, we observed no 
proliferative defect upon transient loss of PSAT1 (Figure 11A&B). In addition, 
changes in HCC1806 actin stress fibers and cell morphology as seen with 
phalloidin staining was also comparable to the MDA-MB-231 cells upon PSAT1 
suppression, wherein cells exhibited loss of elongated stress fibers (Figure 11C). 
Consistent with these findings, the migratory ability of these cells was also 
significantly inhibited in both the wound healing (Figure 12A) and Boyden chamber 
migration assays (Figure 12B) upon PSAT1 suppression. Taken together, these 
results suggest that while PSAT1 silencing does not adversely affect the 
proliferative capacity of serine synthesis-independent TNBC cells, PSAT1 loss 
does significantly inhibit TNBC motility and migration.  
Suppression of PHGDH does not phenocopy the loss of PSAT1 on migratory 
ability  
Given the differential levels of PHGDH between these cell lines, this data 
suggests that the function of PSAT1 in contributing to motility may be separate 
from its primary role in serine synthesis. To more directly examine this, we tested 
both MDA-MB-231 (low PHGDH) and HCC1806 (similar PHGDH expression to 
PSAT1) in the cell motility and migration models under both stable and transient  
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Figure 11: Suppression of PSAT1 in HCC1806 cells does not have an anti-
proliferative effect. A) Representative western blot of PSAT1 levels after 
transient transfection of negative control or PSAT1 siRNA. B) Cell proliferation 
measured via trypan blue exclusion at 24 and 48 hours. Data is shown as mean 
+ SD of viable cell counts and analyzed by 2-way ANOVA, Control p=0.0004, 
PSAT1 p=0.0061. C) Representative images of cytoskeleton F-actin filaments 
upon phalloidin staining in both negative control and PSAT1 siRNA treated 
HCC1806 cells.  
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Figure 12: Decreased motility of HCC1806 cells upon suppression of 
PSAT1. A) Representative wound healing assay images. Quantification is 
presented as % wound closure and shown is mean + SD, p=0.005 as 
determined by unpaired t test. B) Image of cell migration after 24-hours. 
Quantification is presented as area stained and shown is mean + SD, p=0.02 
as determined by unpaired t test. 
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suppression of PHGDH. As PHGDH catalyzes the rate-limiting step in cellular 
serine production, suppression of this enzyme will underscore the relevance of the 
SSP for the inhibitory effects we observe. Similar to previous studies, we found no 
significant effect on proliferation upon loss of PHGDH in the MDA-MB-231 cells 
(Figure 13A&B and Figure 14A&B). Unlike our studies with PSAT1 silencing, 
PHGDH suppression did not affect the cell morphology or the F-actin cytoskeletal 
structure as observed by phalloidin staining (Figure 14C). We also observed no 
significant inhibition in either the wound healing (Figure 15A and Figure 16A) or 
Boyden chamber migration assays (Figure 15B and Figure 16B), contrary to our 
PSAT1 studies. 
Alternatively, we also investigated PHGDH function in the HCC1806 cells 
to demonstrate that these effects are not dependent simply on the dysregulation 
of the serine synthesis pathway. Similar to MDA-MB-231 cells, suppression of 
PHGDH did not affect HCC1806 proliferation (Figure 17A&B), F-actin cytoskeletal 
arrangement compared to control cells (Figure 17C), nor inhibit the migratory 
ability of these cells as observed in wound healing (Figure 18A) or Boyden 
chamber migration (Figure 18B). These results demonstrate that suppression of 
PHGDH does not phenocopy the inhibitory effects on these metastatic 
characteristics that results upon PSAT1 silencing. This suggests that promotion of 
the metastatic characteristics seen in serine synthesis-independent TNBC is 
selective for PSAT1, which may be driven through a function unrelated to its role 
in de novo serine production. 
Suppression of PSAT1 inhibits experimental metastasis  
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Figure 13: PHGDH is dispensable for MDA-MB-231 proliferation in vitro. A) 
Representative western blot analysis demonstrating PHGDH expression in 
MDA-MB-231 cells stably expressing control or PHGDH specific shRNA. B) Cell 
proliferation at 24 and 48 hours with or without PHGDH expression. Data is 
presented as viable cell counts and shown are mean + SD for both control and 
PHGDH shRNA. Results were analyzed by 2-way ANOVA, Control p<0.0001, 
PHGDH p=0.0057. Note: Controls are the same as those represented within the 
PSAT1 experiments. 
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Figure 14: SiRNA suppression of PHGDH in MDA-MB-231 cells has no effect on 
in vitro proliferation. A) Representative western blot analysis demonstrating PSAT1 
expression in MDA-MB-231 transfected with control of PHGDH specific siRNA. B) Cell 
proliferation at 24 and 48 hours after transfection with control or PHGDH siRNA. Data 
is presented as viable cell counts and shown is mean + SD. Results were analyzed by 
2-way ANOVA, p<0.0001. C) Representative images of F-actin filaments after 
phalloidin staining in control or PHGDH siRNA treated MDA-MB-231 cells. 
PHGDH 
β-Actin 
siControl siPHGDH 
A B 
C 
MDA-MB-231 
siControl 
siPHGDH 
Phalloidin DAPI Merge 
24 48
C
el
l C
o
u
n
ts
 (
1X
10
^
4)
55 
 
  
A 
B 
shControl shPHGDH 
0
 
2
4 
h
r 
shControl shPHGDH 
Control PHGDH
0
50
100
%
 W
o
u
n
d
 C
lo
su
re
shRNA
Control PHGDH
0.00
0.02
0.04
0.06
A
re
a 
S
ta
in
ed
shRNA
Figure 15: PHGDH is dispensable for MDA-MB-231 motility in vitro. A) 
Wound healing assays twenty-four hours post-scratch. Data is demonstrated 
as % wound closure and shown are mean + SD, p=0.9810 as determined by 
one-way ANOVA. B) Representative images for Boyden chamber migration 
assays. Quantification is presented as area stained (mean + SD), p=0.6477 as 
determined by one-way ANOVA. Note: Controls are the same as those 
represented within the PSAT1 experiments. 
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Figure 16: SiRNA suppression of PHGDH in MDA-MB-231 cells has no 
effect on motility or migration. A) Representative images of wound healing 
assays of MDA-MB-231 cells with transient suppression of PHGDH. 
Quantification is presented as % wound closure (mean + SD), p=0.2284 as 
determined by unpaired t test. B) Boyden chamber migration assays were 
quantified as mean + SD area stained, p=0.6160 as determined by unpaired t 
test.  
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Figure 17: Loss of PHGDH does not affect HCC1806 proliferation. A) 
Western blot analysis for PHGDH expression in HCC1806 cells after transient 
transfection of control or PHGDH siRNA. B) Cell proliferation at 24 or 48 hours, 
which is presented as viable cell counts (mean + SD). Results were analyzed 
by 2-way ANOVA, Control p=0.0011, PHGDH p<0.0001. C) Representative 
images of phalloidin stained F-actin filaments upon PHGDH suppression in 
HCC1806 cells. 
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Figure 18: Loss of PHGDH does not suppress HCC1806 motility or 
migration potential. A) Representative images and quantification of wound 
healing in HCC1806 cells. Data is presented as % wound closure and shown 
are mean + SD, p=0.0754 as determined by unpaired t test. B) Boyden chamber 
migration assays of HCC1806 cells with or without PHGDH. Quantification is 
demonstrated as area stained (mean + SD), p=0.9563 as determined by 
unpaired t test.   
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To further investigate the potential role of PSAT1 in TNBC metastasis, we utilized 
an established mouse model of experimental metastasis entailing TNBC lung 
nodule formation after tail-vein injection (Figure 19A) [99]. Sixty days post-
injection, we found a significant decrease in the number metastatic foci from MDA-
MB-231 cells lacking PSAT1 compared to mice injected with control cells (Figure 
19B&C). We also found that the no injection mice did not develop tumor nodules 
during the course of this experiment (Figure 19B). To ensure that the decrease 
observed was not due to a loss of anchorage-independent growth, we examined 
both control and PSAT1 silenced cells for the ability to grow in soft agar. We found 
that loss of PSAT1 does not affect anchorage-independent growth of these cells 
(Figure 20), supporting that loss of PSAT1 inhibits the metastatic potential of 
TNBC in vivo.  
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Figure 19: PSAT1 silencing inhibits MDA-MB-231 experimental 
metastasis. A) Outline of experimental protocol for the in vivo study. B) 
Representative H&E staining (4X) of lung sections from individual mice 
receiving no injection or MDA-MB-231 cells with or without stable knock-down 
of PSAT1. Micro-metastases are indicated by the dark punctate areas of 
staining. C) Micro-metastases were quantified as the sum across three image 
fields under 4X magnification from an individual mouse lung section (N = 5, 
shControl; N=7, shPSAT1) and presented as metastatic foci (mean + SD). No 
micro-metastases were found in no injection control animals.  Data analyzed by 
non-parametric unpaired t-test with Mann-Whitney U test, * p = 0.0051. 
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Figure 20: Suppression of PSAT1 does not affect anchorage-
independent growth of MDA-MD-231 cells. A) Soft agar colony 
formation assays of MDA-MB-231 cells stably expressing control or 
PSAT1-specific shRNA. Shown are representative images of colonies 
two weeks after plating from two independent experiments. B) 
Quantification of soft agar assays. Data points are individual 
experiments. Statistical analysis not performed as n=2. 
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Discussion 
In this report, we demonstrate that PSAT1 expression increases in higher grades 
of TNBC. Unlike PHGDH, no genetic amplifications have been observed for 
PSAT1 and elevated levels are the result of oncogenic pathways that are activated 
as TNBC progresses. Multiple studies have previously demonstrated that 
activating transcription factor 4 (ATF4) can control PSAT1 expression. ATF4 has 
been shown to regulate PSAT1 in several different cancer types, including breast 
cancer [46-49]. Importantly, in all tumors examined, ATF4 activation increases 
expression of not only PSAT1 but also enzymes within the entire serine synthesis 
pathway, including PHGDH and PSPH. As this is not selective for PSAT1 
expression, as we have found in the MDA-MB-231 cells, this suggests other 
regulatory mechanism(s) in TNBC that may be directly controlling PSAT1.  
Within breast cancer, the transcription factors TAZ/YAP have been shown 
to have higher activity in basal breast cancer subtype and to selectively induce 
expression of PSAT1 in TNBC, specifically in the MDA-MB-231 cell line [60]. TAZ 
expression is activated by the overexpression of the transcription factors Twist and 
Snail [61]. This increased TAZ/YAP expression/activity has been correlated with 
high histological grade breast cancer [61] as well as the promotion of oncogenic 
transformation, enhancing tumorigenic properties, induction of cancer stem cell-
like activity and resistance to breast cancer drug therapies [100]. TAZ/YAP have 
also been linked to increased metastatic capability in breast cancer [101]. In 
addition, PSAT1 has also been shown to be induced by mTOR and be under the 
regulation of the PI3K/Akt/mTOR pathway in breast cancer [62]. This pathway has 
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been demonstrated to increase as breast cancer progresses with the highest 
expression levels correlating with higher grade mammary tumors [102]. The 
PI3K/Akt/mTOR pathway has also been highly associated with metastasis [102]. 
Taken together, multiple pro-tumorigenic pathways that mediate breast cancer 
progression converge to increase PSAT1 expression that then may contribute to 
the metastatic potential of TNBC.    
We now show that suppression of PSAT1 in two defined serine synthesis-
independent TNBC cell lines does not affect cell proliferation, yet, there is a 
significant reduction in the in vitro metastatic capabilities of cell migration and 
invasion due, in part, to alterations in F-actin cytoskeletal rearrangement and cell 
morphology. Despite substantial PHGDH expression in a representative cell type 
(HCC1806), this anti-metastatic effect seems to be selective for PSAT1 as PHGDH 
suppression did not phenocopy loss of PSAT1. Further, PSAT1 contribution to 
metastatic activity extended in vivo as protein suppression significantly inhibits 
tumor nodule formation without disrupting the anchorage-independent growth of 
these cells. As the tail-vein injection experimental model is limited in its 
assessment of the entire metastatic cascade, particularly tumor cell escape from 
a primary tumor, future examination of effects of PSAT1 loss in metastatic potential 
from primary orthotopic tumors will be necessary to fully assess its function in 
TNBC metastasis. Yet, these results suggest that PSAT1 may have an alternate 
function in contributing to TNBC metastasis that is separate from its role in serine 
synthesis. 
It is important to note that these studies were carried out in TNBC cell types 
64 
 
that have been designated as independent of de novo serine synthesis. While 
expressing SSP enzymes, there is little to no metabolic flux through the SSP in 
these cells, thereby necessitating a requirement for external serine for cell 
proliferation. Conversely, it is well documented that there are TNBC cell lines and 
patient tumors that are designated as serine synthesis-dependent. This subset 
exhibits extremely high expression of PHGDH primarily due to genetic 
amplifications. This drives increased flux through the SSP and allows for growth in 
serine lacking conditions. Yet, even in serine complete conditions, suppression of 
PHGDH or PSAT1 causes a significant reduction in cell proliferation in vitro due to 
disruptions in glutaminolysis and nucleotide production [49,87]. In addition, 
suppression of PHGDH, or the use of PHGDH inhibitors, have been shown to have 
a detrimental effect on the growth of these tumors in vivo [86,87].  
While serine synthesis-dependent tumor cells are sensitive to PHGDH 
inhibitors, these compounds had no effect on serine synthesis-independent cell 
types [86] and furthermore did not affect serine flux within this subset [87]. 
Consistent with these results, suppression of PSAT1 or PHGDH also did not affect 
the proliferative capacity in the MDA-MB-231 cells in our studies [55,87]. 
Conversely, others have also demonstrated that overexpression of PSAT1 in other 
independent cell types was able to increase proliferation and metastatic capability 
[49]. Whether these effects were directly due to increased de novo serine synthesis 
is unclear but supports a role for PSAT1 in promoting cell metastasis. These 
previous findings coupled with our results demonstrating the metastatic inhibitory 
65 
 
effects upon suppression of PSAT1 indicate a selective role for PSAT1 and not a 
result of dysregulation of de novo serine production. 
While these results suggest an activity for PSAT1 apart from serine 
synthesis, its pro-metastatic function(s) in these cell types is unclear. There have 
been several mechanisms proposed for non-canonical functions of PSAT1. For 
example, in esophageal cancer, PSAT1 acts upstream of Akt that controls 
downstream targets of GSK-3B and snail, which work to promote tumor 
progression and enhance metastatic characteristics [72]. In non-small cell lung 
cancer, it has been suggested that PSAT1 inhibits the degradation of cyclin D1, 
which leads to an alteration in the Rb-E2F pathway [81]. However, despite these 
potential non-canonical activities of PSAT1, decreased PSAT1 generally resulted 
in loss of cell proliferation. This is not evident in our systems and suggests another 
yet unknown function towards metastatic potential. Alternatively, Yang et al 
postulates that TAZ/YAP’s regulation of PSAT1 is driven by a need to generate α-
ketoglutarate in order to feed into the TCA cycle. They found that the serine-
independent MDA-MB-231 cell line exhibits a high level of TAZ/YAP and are 
designated as glutamine dependent [60]. This observation from Yang et al 
combined with the implications of TAZ/YAP in metastasis indicates that this might 
be a mechanism in which PSAT1 is contributing to the metastatic characteristics 
of TNBC. In addition, the observed disruption in actin fibers upon suppression of 
PSAT1 indicates that PSAT1 may contribute particularly to metastatic potential by 
maintenance of cytoskeleton structure in promoting cell motility. 
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Given the extent of PSAT1 expression across TNBC, even within subsets 
not dependent on de novo serine synthesis, suggests that it may serve an alternate 
function. These studies support a non-canonical role as loss of PHGDH did not 
phenocopy PSAT1 suppression with regards to metastatic potential. Continued 
work will be necessary to define whether PSAT1 functions in a similar manner in 
additional TNBC cell types and the mechanisms by which PSAT1 supports TNBC 
metastasis. Yet, despite the uncertainty of these mechanism, we believe that 
PSAT1 is an appealing potential therapeutic target for TNBC patients; particularly 
in suppressing metastatic spread. 
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Extended Results and Discussion 
 In addition to the PHGDH suppression experiments that were done, we also 
performed metastatic characteristics assays in the presence of exogenous serine 
(Figure 21). Although the culture media for MDA-MB-231 cells contain 400uM 
serine, we wanted to ensure that serine did not become limiting in our studies and 
that our results are truly independent of a requirement for de novo serine synthesis 
and utilization. We observed that the addition of exogenous serine (2.5mM) did not 
rescue the PSAT1 suppression phenotype in either our wound healing (Figure 21) 
or our migration assays (Figure 22). Since addition of exogenous serine was 
unable to rescue this phenotype these data further suggests that PSAT1 
contributes to TNBC metastasis independent of its role in serine synthesis. 
Thus, to address the non-canonical function of PSAT1 that we observed in 
these studies, we have preliminarily attempted to identify potential binding partners 
of PSAT1 that could contribute to its anti-metastatic function. Database analysis 
revealed several potential binding partners of PSAT1 that were identified through 
large high throughput interaction screens. Two proteins that may influence this 
metastatic phenotype are of particular interest. Tissue inhibitor of 
metalloproteinases 2 (TIMP2), when expressed and active, typically inhibits tumor 
growth, invasion, and metastasis via its inhibition of the matrix metalloproteinases 
(MMPs) [103]. However, there have been reports of TIMP2 having multiple roles 
and that in breast cancer there is evidence to support TIMP2’s involvement in 
promoting proliferation, protecting against apoptosis, and correlating to poorer 
progression-free survival [103] The contradictory roles of TIMP2 as both a 
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Figure 21: Exogenous serine does not rescue PSAT1 suppression on cell 
motility. Representative images of wound healing at 24 hours post scratch with or 
without the addition of 2.5mM exogenous serine for the MDA-MB-231 cells transfected 
with shRNA against control, PSAT1, or PHGDH. Data analyzed by one-way ANOVA, 
**** p<0.0001, ** p=0.0035. 
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Figure 22: Exogenous serine does not rescue effect of PSAT1 suppression 
on cell migration. A) Representative images of Boyden chamber migration assays 
24 hours post seeding with or without the addition of exogenous serine for the MDA-
MB-231 cells transfected with shRNA against control, PSAT1, or PHGDH. B) 
Quantification of migration assays under normal serine conditions. Data analyzed 
by one-way ANOVA, p=0.0021. C) Quantification of migration assays with 2.5mM 
Serine. Data analyzed by one-way ANOVA, p=0.0264. 
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correlator with low recurrence and poorer prognosis [104] could possibly be due to 
its interacting partners. To confirm an interaction between PSAT1 and TIMP2, I 
performed a co-immunoprecipitation assay (Figure 23) and found an association 
between PSAT1 and TIMP2. It is plausible that the interaction of TIMP2 and 
PSAT1 interferes with the ability of TIMP2 to inhibit MMPs and thus may promote 
a pro-metastatic phenotype. However, upon loss of PSAT1, the TIMP2-PSAT1 
interaction is abolished and TIMP2 is able to inhibit the MMPs and thus result in 
the inhibition of the metastatic characteristics. Further studies to evaluate this 
mechanism include endogenous co-immunoprecipitation studies to confirm the 
interaction between PSAT1 and TIMP2. In addition, MMP activity assays would 
also be performed utilizing both control and PSAT1 suppressed cells in order to 
determine if PSAT1 suppression, and potentially loss of PSAT1-TIMP2 interaction, 
has an effect on MMP activity. 
 A second potential interacting protein suggested was ras responsive 
element binding protein 1 (RREB1). This protein’s drosophila homolog, hindsight 
(HNT), has been shown to be involved in collective cell migration, the regulation of 
cell adhesion, and to play a part in cell morphology [105]. These affects were 
shown to occur via the JNK and Stat pathways. Additionally, it was shown in breast 
epithelial cells that the expression of RREB1 was required for cell spreading and 
migration as suppression of RREB1 did not affect cell viability but rendered the 
cells immobile [105]. Thus, in an alternative mechanism, the dramatic differences 
that we observed on cell morphology and migration upon PSAT1 suppression 
could be attributed to a loss of the interaction between PSAT1 and RREB1. Either 
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Figure 23: PSAT1 and TIMP2 are binding partners. Western blot analysis 
following immunoprecipitation of FLAG-PSAT1. Lysates were 
immunoprecipitated using M2-FLAG beads and membranes were 
immunoblotted for either PSAT1 or GFP, as a measure of TIMP2 expression. 
FLAG-PSAT1     -       +                   -          + 
GFP-TIMP2       -       -                  -          + 
IP: FLAG 
IB: GFP 
IP: FLAG 
IB: PSAT1 
PSAT1 GFP (TIMP2) 
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of these mechanisms may be valid means by which PSAT1 is contributing to the 
metastatic characteristics of TNBC independent of its metabolic activity. Further 
work would need to be done to fully investigate PSAT1’s role as it may relate to 
these pathways. 
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CHAPTER 3 
PHOSPHOSERINE AMINOTRANSFERASE 1 (PSAT1) AND THE SERINE 
SYNTHESIS PATHWAY ALTERS SENSITIVITY TO 4-HYDROXYTAMOXIFEN 
TREATMENT IN ESTROGEN-RECEPTOR POSITIVE BREAST CANCER 
Introduction 
 Breast cancer is the most common cancer that afflicts US women [3]. 
Importantly, breast cancer is not a singular disease, but is characterized by several 
different histological subtypes that have now been identified. Estrogen receptor 
positive breast cancer (ER+BC) is the most common breast cancer subtype [3] 
and it accounts for 65% to 75% of all breast cancer cases [3]. ER+BC has a higher 
incidence rate in older white women living in more western countries, like the 
United States [7]. ER+ tumors express the estrogen receptor and the 
growth/proliferation of these tumors are driven by estrogens binding to the 
estrogen receptor and promoting transcription of pro-proliferative genes [10]. As 
these tumors are reliant upon this estrogen-driven growth, therapies that target the 
estrogen signaling pathway have become successful treatment options for patients 
and much of the decline in mortality associated with breast cancer is credited to 
their success [3].  
All endocrine therapies target portions of estrogen signaling through 
different mechanisms. The first clinical endocrine therapy, Tamoxifen, was 
originally classified as an anti-estrogen because it functions as an estrogen  
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antagonist in the breast, however, in other tissues it has agonistic properties [10]. 
It has thus been reclassified as a selective estrogen receptor modulator (SERM). 
Tamoxifen can function on both estrogen receptor α (ERα) and estrogen receptor 
β (ERβ) [106].  When tamoxifen is bound to ERβ it acts as a pure antiestrogen, 
however, when tamoxifen is bound to ERα it can act as a partial agonist [106]. 
Tamoxifen’s primary mechanism of action in the breast is through competition with 
estrogens binding to the estrogen receptor that results in the inhibition of the 
estrogen driven pro-proliferative transcription program [12,13]. In addition to 
binding to the estrogen receptor, tamoxifen has also been demonstrated to recruit 
corepressors to the estrogen response elements in the promoters of estrogen 
receptor target proteins as an additional mechanism of inhibition [106]. 
Fulvestrant, ICI, is considered a pure antiestrogen that exhibits no agonistic 
activity [10,107]. Fulvestrant is also classified as a selective estrogen receptor 
degrader (SERD) [9]. Fulvestrant differs from tamoxifen in its mechanism of action 
as fulvestrant binds to the estrogen receptor and increases protein degradation 
resulting in attenuation of the estrogen driven pro-proliferative transcriptional 
program [12]. Fulvestrant also has a higher binding affinity for ER compared to 
tamoxifen and is a more potent inhibitor of cell proliferation [107]. Fulvestrant is 
often given to patients that have had disease progression following tamoxifen 
treatment [10]. Fulvestrant can be used as a second line treatment because it has 
been shown to have no cross-resistance with tamoxifen [107]. 
Despite numerous effective therapeutic options for patients with ER+BC 
and a better patient prognosis, there are more deaths linked to ER+BC than any 
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other subtype [11]. This is largely attributed to resistance to endocrine therapy, 
which can be classified as either innate or acquired resistance. Innate, or de novo, 
resistance relates to patients that have no initial response to endocrine therapy 
[11]. Acquired resistance includes patients that initially respond to endocrine 
therapy but then experience disease recurrence or progression [11]. Clinically, the 
issue of endocrine resistance affects between 10% and 15% of all patients within 
five years of diagnosis [22]. By 15 years following diagnosis, it is estimated that 
30% of ER+BC patients will become resistant to endocrine therapies [22]. 
With the potential for endocrine resistance to affect 30% of all ER+BC 
patients, there is an increased need to identify genes that may promote loss of 
response to these therapeutic options. One of the genes that has been linked to 
endocrine resistance is phosphoserine aminotransferase 1 (PSAT1) [82]. PSAT1, 
along with phosphoglycerate dehydrogenase (PHGDH) and phosphoserine 
phosphatase (PSPH) comprise the serine synthetic pathway. PSAT1 has been 
implicated in numerous different cancer types as contributing to proliferation, 
resistance, metastasis and has been implicated in breast cancer resistance to 
endocrine therapy [49,57,58,65,72,81,82,97]. In these initial reports concerning 
PSAT1 in breast cancer, it was determined that the expression of the PSAT1 
transcript correlated to poorer progression-free survival in ER+ patients that were 
treated with tamoxifen with the PSAT1 correlation being the most significant [82]. 
This was later confirmed at the protein level [97] and this study also suggested an 
increase in PHGDH expression in tamoxifen insensitive breast cancer [97]. 
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Together, these results suggest a potential metabolic requirement for SSP acting 
in promoting endocrine resistance. 
In this report, we examine the clinical relevance of PSAT1 and PHGDH in 
tamoxifen-resistant ER+BC and using in vitro models seek to determine if 
sensitivity to tamoxifen treatments or antiestrogens can be altered by manipulation 
of PSAT1 expression. 
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Methods and Materials 
Chemicals 
 (Z)-4-Hydroxytamoxifen was obtained from Sigma (H7904) and was 
dissolved in 100% pure Ethyl Alcohol (Sigma – E7023). ICI 182,780 (Fulvestrant) 
was obtained from TocrisBioscience (CAS No: 129453-61-8) and was dissolved in 
dimethyl-sulfoxine (Fisher BioReagents – BP231). Concentrated stock solutions 
were prepared, aliquoted and stored at -20°C for a period of 30 days. Diluted 
working stocks were prepared fresh for each application. 
Cell Culture 
MCF-7 cells were purchased from ATCC. LCC9 and LY2 cells were 
provided by Dr. Carolyn Klinge under an approved material transfer agreement 
from Dr. Robert Clarke [108,109]. All cells were cultured in IMEM supplemented 
with 5% FBS and gentamicin. All cells were incubated at 37° in 5% CO2. 
Plasmid Construction and Transfections 
 Human PSAT1 was generated from cDNA prepared from the LCC9 cell line. 
RNA was extracted using the RNeasy kit (Promega) and 1mg of RNA was used to 
produce cDNA using the reverse transcriptase kit (Thermo) with random primers. 
Primers homologous to the 5’ and 3’ ends of the mature RNA encoding for PSAT1 
were adapted to include restriction sites for ECOR1 (5’) and BAMH1 (3’). 
Polymerase chain reactions were performed to amplify PSAT1 from LCC9 cDNA 
preparation. PCR products were separated via gel electrophoresis and bands 
corresponding to the correct PCR product were excised from the gel and purified. 
PSAT1 fragments underwent restriction digest with ECOR1 and BAMH1 and then 
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were ligated into the pcDNA3 vector that was similarly digested. Ligations were 
then transformed and grown on LB agar plates with ampicillin. Isolated colonies 
were cultured in LB broth and ampicillin for 24 hours and plasmids were isolated 
via the Qiagen Miniprep kits. Plasmids, encoding either PSAT1 gene or empty 
vector were verified by sequencing. Plasmids were then transfected into the MCF-
7 cell line using the Polyplus jetPRIME reagent according to manufacturer’s 
protocol and clonal selection for PSAT1 expression was performed using 
geneticin. 
siRNA and shRNA Transfections 
 PSAT1 shRNA and Control shRNA were purchased from Sigma. ShRNAs 
were transfected into LCC9 cells using the Polyplus jetPRIME reagent according 
to manufacturer’s protocol. Clonal selection for gene silencing was performed 
using puromycin. The sequences for the shRNA and siRNA species are as follows: 
PSAT1 shRNA: 5’-
CCGGGCACTCAGTGTTGTTAGAGATCTCGAGATCTCTAACAACACTGAGTG
CTTTTTG-3’, Control shRNA: 5’- 
CCGGCAACAAGATGAAGAGCACCAACTCGAGTTGGTGCTCTTCATCTTGTT
GTTTTT-3’, PHGDH RNAi: 5’-CGACAGGUUGCUGAAUGA-3’, non-targeting pool 
RNAis: 5’-UGGUUUACAUGUCGACUAA-3’, 5’-UGGUUUACAUGUUGUGUA-3’, 
5’-UGGUUUACAUGUUUUCUGA-3’, 5’-UGGUUUACAUGUUUUCCUA-3’. 
Immunoblot Assays 
 Whole-cell lysates were prepared in IP Lysis Buffer (Pierce) containing 
protease and phosphatase inhibitors. Proteins were separated on 10% SDS-
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polyacrylamide gels and transferred to PVDF. Membranes were blocked with 5% 
non-fat dry milk in TBS-T and subsequently probed with 1:1000-fold dilution of anti-
PSAT1 (Proteintech, 10501-1-AP) or anti-PHGDH (Sigma HPA021241) antibodies 
for 16 hours at 4°. Washed membranes were then incubated with 1:5000 dilution 
of HRP-conjugated anti-rabbit or anti-mouse secondary antibodies. Protein 
detection was done by exposure to ECL Prime chemiluminescent reagent (GE 
Healthcare). Protein loading was assessed using anti-β-actin antibody (Sigma, 
A2228). Densitometry was performed via ImageJ. 
Stable Isotype Resolved Metabolomics (SIRM) 
 MCF7 or LY2 cells were cultured in glucose-free IMEM supplemented with 
5% dialyzed serum and 1g/L 13C6 – glucose (Sigma) for 48 hours. Metabolism was 
quenched via exposure to cold acetonitrile and cell metabolites were extracted 
using an acetonitrile/chloroform/H2O mixture. Polar metabolites were 
subsequently lyophilized and analyzed by Liquid Chromatography Mass 
Spectrometry (LCMS) in collaboration with the Resource Center for Stable Isotype 
Resolved Metabolomics Core facility at the University of Kentucky. 
Treatments and Response 
 Cells were treated with either 4-hydroxytamoxifen (4-OHT) or ICI 182,780 
(ICI) for a period of four days [110]. Treatment response was measured by 
FluoReporter Blue Fluorometric dsDNA Quantitation Kit (Molecular Probes F-
2962). In brief, cells were plated at 5,000 (MCF-7) or 2,500 (LCC9) cells per well 
on day 0. On day 1 cells were treated with indicated concentrations of either 4-
OHT or ICI. On day 4 the plates were collected and analyzed according to 
80 
 
manufacturer’s protocol. Treatment responses were calculated by percent 
decrease in fluorescence compared to the vehicle control. 
Quantitative-Real Time Polymerase-Chain Reaction 
 MCF-7 or LCC9 cells were collected and total RNA was isolated using the 
RNeasy Mini Kit (Qiagen). One milligram of RNA was converted to cDNA using the 
High-Capacity RNA-to-cDNA kit (appliedbiosystems) according to the 
manufacture’s protocol. Samples were then analyzed for qPCR via the TaqMan 
Fast Advanced (appliedbiosystems) system with human probes for PSAT1 
(Hs00795278_mH), PHGDH (Hs00198333_m1), and ACTB (Hs01060665_g1). 
Kaplan Meier Analysis 
 Retrospective analysis of specific gene expression on patient survival was 
performed by Kaplan-Meier analysis on de-identified patient clinical data obtained 
from either an IRB-approved institutional biorepository [111] or within the online 
database KM Plotter (kmplot.com) [112]. ER+BC patients treated with tamoxifen 
or any endocrine therapy were stratified for differential PSAT1 or PHGDH 
expression [113]. The hazard ratio (HR) with 95 % confidence intervals and the 
logrank p value are indicated. 
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Results 
Clinical relevance of PSAT1 in ER+ patients treated with tamoxifen 
It has been previously observed that PSAT1 transcript and protein levels 
correlated with a poorer progression-free survival in ER+ patients treated with 
tamoxifen [82,97]. We initially validated these prior studies in two separate patient 
cohorts, including an institutional clinical population and individuals within the KM 
Plotter database. All patients presented with ER+BC and had undergone 
tamoxifen treatment as the sole endocrine therapy. In agreement, analysis of both 
patient cohorts revealed a negative correlation between higher PSAT1 expression 
and disease-free survival (Figure 24A) or relapse-free survival (Figure 24B). 
These results, as well as the previous studies, suggest that PSAT1 may be 
involved in tamoxifen resistance of ER+BC patients. 
Manipulation of PSAT1 expression can alter sensitivity to tamoxifen therapy 
Prior studies have established in vitro models used to investigate the 
mechanisms that drive endocrine sensitive breast cancer to endocrine resistance 
[114]. One model system utilizes the sensitive MCF-7 ER+ cell line and its resistant 
derivatives. These derivative cell lines were generated by exposing parental MCF-
7 cells to increasing concentrations of endocrine therapies over an extended 
period of time (Figure 25A). Acquired from our collaborator, Dr. Carolyn Klinge, 
we employed this system to assess the contribution of PSAT1 and the SSP in 
general to tamoxifen sensitivity. We initially found that there was differential 
expression of PSAT1 between the resistant (LCC9 and LY2) and parental (MCF-
7) lines (Figure 25B). Transcript and protein analysis showed increasing levels of 
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Figure 24: Clinical relevance of PSAT1 in Tamoxifen treated ER+BC. A) 
Disease-free survival of ER+ patients treated with tamoxifen stratified by above 
(n=33) or below (n=32) the median PSAT1 expression. Kaplan-Meier analysis was 
performed from previous transcriptomic analysis on a patient cohort within an 
institutional biorepository. B) Kaplan-Meier analysis of patient outcomes was done 
using KM Plotter database. Relapse-free survival of ER+ patients treated with 
tamoxifen stratified by low (n=73) or high (n=37) PSAT1 expression. 
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Figure 25: Differential PSAT1 expression between sensitive and resistant 
cell lines. A) Schematic summarizing the in vitro model system used in these 
studies. B) Representative western blots demonstrating the differential 
expression between the endocrine sensitive MCF-7 parental line and the 
endocrine resistant derivatives (LCC9 and LY2). Densitometry analysis was 
performed using ImageJ. C) Transcript levels, represented as ΔCT, of PSAT1 
between the different cell lines. 
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PSAT1 in the resistant cell types (Figure 25 B and C). Importantly, the MCF-7 
sensitive cell line exhibits no PSAT1 expression as compared to the resistant lines. 
To determine whether the increase in enzyme expression corresponds to elevated 
SSP activity, we used stable isotope resolved metabolomics (SIRM) to evaluate 
glucose carbon incorporation into de novo serine production (Figure 26A). Using 
the LY2 cells, as they demonstrated the greatest enzyme expression, we found 
elevated SSP in the resistant cell line as evidence of greater levels of 13C carbon 
from glucose into serine (m+3 serine), while activity in the MCF-7 line was below 
detectable limits (Figure 26B). 
 This differential expression of SSP enzymes, particularly PSAT1, between 
sensitive and resistant lines indicates that SSP activity may influence tamoxifen 
sensitivity. To investigate this potential metabolic consequence, we chose to alter 
PSAT1 levels in these cell models as endocrine sensitive MCF-7 cells do not 
express this SSP enzyme. First, PSAT1 was overexpressed in the MCF-7 cells 
(Figure 27A-B) to determine its effect on 4OHT response compared to the 
parental cells. Overexpression of PSAT1 in the MCF-7 cell line reduced the 
sensitivity of these cells at two different concentrations of 4-OHT (Figure 27C). 
Exposure to 100 or 500nM 4OHT led to 40-45% reduction in MCF-7 cell 
proliferation. Yet, PSAT1 expressing cells had reduced sensitivity to 4OHT (22-
25% decrease respectively). Conversely, the contribution of PSAT1 to 4OHT 
resistance was also examined under loss of PSAT1 in the resistant LCC9 cell line. 
Using stable shRNA, PSAT1 was suppressed in the LCC9 cells (Figure28A) and 
resulted in a sensitization to 4OHT treatment (Figure 28B). Taken together, these  
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Figure 26: Metabolomic differences between endocrine sensitive and endocrine 
resistant cell types. A) Schematic demonstrating serine labeling patterns derived from 
13
C-Glucose labeling. B) 
13
C-Serine levels for the endocrine sensitive parental MCF-7 
cell line and the endocrine resistant derivative (LY2) cell line. 
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Figure 27: Overexpression of PSAT1 reduces sensitivity to 4-
hydroxytamoxifen. A) Representative western blot demonstrating the level of 
overexpression of PSAT1 in the MCF-7 cells. B) Transcript levels demonstrating 
the extent of PSAT1 overexpression in the MCF-7 cells. p=0.0005 as determine 
by unpaired t test. C) Response to 4OHT, measured as percent decrease in cell 
proliferation, for both the MCF-7 empty vector and MCF-7 PSAT1 
overexpression cell lines. p=0.0006 100nM 4OHT, p=0.0002 500nM 4OHT as 
determined by 2-way ANOVA with Tukey’s comparison test. 
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Figure 28: Suppression of PSAT1 increases sensitivity to 4-
hydroxytamoxifen. A) Representative western blot demonstrating the 
suppression of PSAT1 in the LCC9 cell line. B) Response to 500nM 4OHT, 
measured as percent decrease in cell proliferation, for both the LCC9 shControl 
and LCC9 shPSAT1 cell lines. p=0.0001 as determined by unpaired t test. 
B A 
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results indicate that PSAT1 and SSP activity may be a contributing factor in the 
resistance to tamoxifen of ER+ patients. 
Clinical relevance of PHGDH in ER+ patients treated with tamoxifen 
 As part of the prior study on PSAT1 protein expression in clinical ER+BC 
samples, the authors also suggested that PHGDH might also be contributing to 
resistance in ER+ patients treated with tamoxifen [97]. This was attributed to the 
finding of increased expression of PHGDH in the tamoxifen treated patients that 
exhibited poorer clinical outcomes. However, no statistical or experimental 
analysis were performed to validate this potential relevance of PHGDH. Using KM 
plotter, we sought to determine if this observation could be associated with patient 
survival. Analyzing the same patient cohort used for PSAT1 (Figure 24), we found 
that patients with higher PHGDH expression also had significantly poorer relapse-
free survival compared to patients with low PHGDH expression (Figure 29). 
Similar to PSAT1, suppression of PHGDH also sensitized LCC9 endocrine 
resistant cells to 4OHT treatment (Figure 30). 
Clinical correlation involving SSP enzymes and in vitro sensitivity to 
endocrine therapy is selective for tamoxifen 
 Endocrine therapies encompass several different approaches to suppress 
estrogen signaling. Beyond 4OHT, the pure antiestrogen Fulvestrant and 
aromatase inhibitors are frequently used in the clinic. Inevitably, patients will also 
become resistant to these endocrine therapies as well. We next wanted to 
determine whether SSP enzymes contributed to resistance to other endocrine 
treatments. Within in vitro experiments, we examined the effect of PSAT1 
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Figure 29: Clinical relevance of PHGDH in ER+ patients treated 
with tamoxifen. KM Plotter was used to determine relapse-free 
survival of ER+ patients treated with tamoxifen that was stratified by 
low (n=486) or high (n=184) PHGDH expression. 
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Figure 30: Suppression of PHGDH increases sensitivity to 4-
hydroxytamoxifen. A) Representative western blot demonstrating the 
suppression of PHGDH in the LCC9 cell line. B) Response to 500nM 4OHT, 
measured as percent decrease in cell proliferation, for both the LCC9 siRNA 
Control Pool (siCP) and LCC9 siPHGDH cell lines. p=0.0197 as determined by 
unpaired t test. 
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suppression on sensitivity to ICI in LCC9 cells, as the LCC9 cell line is also 
resistant to ICI treatment [109]. We treated either control or PSAT1 suppressed 
cells with different concentrations of ICI and found no significant difference in cell 
proliferation (Figure 31A). To determine if this result extended to clinical data, we 
analyzed a patient cohort that was inclusive of ER+BC patients treated with any 
endocrine therapy. We then stratified these patients based on transcript levels of 
either PSAT1 (Figure 31B) or PHGDH (Figure 31C). When all endocrine therapies 
are included, significant association between high expression of the SSP enzymes 
and relapse-free survival is lost (Figure 31), contrary to what we observed with 
tamoxifen as the sole therapy (Figure 24, Figure 29). These data suggest that the 
contribution of PSAT1 or PHGDH to endocrine resistance may be limited to 
tamoxifen therapy. 
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Figure 31: Correlation between SSP enzymes and relapse-free survival and in 
vitro sensitivity to endocrine therapy is selective for tamoxifen. A) LCC9 control 
of PSAT1 suppressed cells in response to ICI treatment at different concentrations. 
Response measured as percent decrease in cell proliferation. p>0.9999 50nM ICI, 
p=0.9774 100nM ICI, p>0.9999 500nM ICI as determined by 2-way ANOVA with 
Tukey’s comparison test. B) Relapse-free survival of ER+ patients treated with all 
endocrine therapies stratified by low (n=121) or high (n=60) PSAT1 expression. C) 
Relapse-free survival of ER+ patients treated with all endocrine therapies stratified 
by low (n=498) or high (n=244) PHGDH expression. Kaplan-Meier analysis 
performed with KMPlotter database. 
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Discussion 
 In this chapter we have demonstrated that both PSAT1 and PHGDH are 
correlated with poorer relapse-free survival in ER+ patients that were solely treated 
with tamoxifen. This agrees with previously published findings that implicated 
PSAT1 in tamoxifen resistance [82,97]. Furthermore, we showed that manipulation 
of PSAT1, either via overexpression in a tamoxifen sensitive model or suppression 
in a tamoxifen resistant model, can alter sensitivity to 4OHT treatment. In addition, 
loss of PHGDH was also shown to alter sensitivity to 4OHT.  These data indicate 
that the serine synthetic pathway contributes to tamoxifen resistance. Additionally, 
these effects seem to be selective for tamoxifen as both in vitro and clinical data 
failed to show any correlation between expression of serine synthetic enzymes and 
sensitivity to ICI or with inclusion of other endocrine therapies with respect to the 
KM analysis.  
We speculate that the differences that we have observed between 4OHT 
and ICI treated cells could be related to their different mechanisms of action. 
Tamoxifen is a selective estrogen receptor modulator and its primary mode of 
action is through the binding to the estrogen receptor, competing with estrogens, 
resulting in inhibition of the estrogen driven pro-proliferative transcription program 
[12,13]. There is also evidence that tamoxifen can function independently of 
binding to the estrogen receptor via induction of transforming growth factor-β 
(TGF-β) and through reduction of circulating insulin-like growth factor I (IGF-I) [13]. 
Fulvestrant is a “pure”-antiestrogen or a selective estrogen receptor down-
regulator [12]. Fulvestrant binds to the estrogen receptor, impairs its dimerization, 
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and increases protein degradation and turn-over. This results in the complete 
attenuation of downstream estrogen signaling [12]. Importantly, in tamoxifen 
treated conditions, the estrogen receptor remains expressed; in contrast, during 
fulvestrant treated conditions there is a loss of the estrogen receptor [12]. This 
combined with our results suggest that tamoxifen resistance mediated by PSAT1 
and PHGDH may be reliant upon either the maintenance of the estrogen receptor, 
its co-activators, or one of its gene targets. While the requirement for maintenance 
of ER as it relates to PSAT1 and PHGDH-mediated resistance would need further 
investigation, there is literature evidence to support this notion. MYC is a known 
target of estrogen receptor signaling and its function as well as its role in endocrine 
resistance requires maintenance of the ER [115]. 
Although these results suggest there might be a requirement for ER 
maintenance, the mechanism(s) by which PSAT1 and PHGDH are contributing to 
tamoxifen resistance is unclear. It could be through oncogenic activation of the 
SSP by proteins such as MYC, which has already been suggested to activate 
transcription of PSAT1 and PHGDH [52] and both (SSP and MYC) have been 
implicated in endocrine resistance [82,97,116]. Or the SSP-mediated resistance 
could be related to one of the metabolic consequences of de novo serine 
synthesis. Previous literature has suggested that glutamine is required for the pro-
proliferative estrogen-driven signaling cascade in ER+BC [115]. It has also been 
suggested that while uptake of glutamine is independent of estrogen signaling, this 
process may also require maintenance of ER expression [115], similar to what our 
results suggest for PSAT1 and PHGDH-mediated resistance. Additionally, PSAT1 
95 
 
is responsible for the second processing step of intracellular glutamine as it 
converts glutamate to α-ketogluterate [28], which connects glutamine 
consumption, the SSP, and endocrine resistance to maintenance of ER 
expression. Alternatively, epigenetic changes have also been proposed as a 
mechanism for tamoxifen resistance [22]. These changes include increases in 
hypomethylated promoter regions of oncogenic genes and hypermethylated 
promoter regions of tumor suppressors [22]. There is also evidence to suggest that 
in breast cancer the ER cofactors are under epigenetic control and that 
dysregulation of these cofactors is correlated with resistance to tamoxifen therapy 
[22]. As stated, PSAT1 and PHGDH are both members of the serine synthetic 
pathway along with PSPH. This pathway diverges from the glycolytic pathway at 
3-phosphoglycerate for de novo synthesis of serine [28]. Downstream, serine can 
be used in one carbon metabolism to generate s-adenosyl-methionine (SAM) 
[117]. SAM is the methyl donor for the methylation of nucleic acids, proteins, and 
lipids and there has been evidence to support that the levels of serine dictate the 
levels of SAM [117]. 
Given the literature and our results, we hypothesize that PSAT1 and 
PHGDH are contributing to tamoxifen resistance through de novo serine synthesis 
by both processing of glutamine and the downstream generation of SAM and 
subsequent epigenetic changes but further investigation into this area would be 
needed to confirm that this is the mechanism in which the serine synthetic pathway 
is contributing to resistance (Figure 32). In addition, it would be interesting if 
treatment with PHGDH inhibitors [86,118] would be able to recapitulate the effects  
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Figure 32: Model of SSP contribution to endocrine resistance. This model 
represents the suggested mechanisms by which PSAT1 and PHGDH are 
contributing to tamoxifen resistance in ER+BC. In sensitive conditions there is 
an inhibition of estrogen signaling and low expression of ER target genes. In 
resistant condition there is increased ERα signaling, despite a tamoxifen (4-
hydroxytamoxifen) occupied ER, and increased expression of ER target genes. 
One target gene, cMYC, is increased in resistant conditions and has been 
shown to increase expression of PSAT1 and PHGDH but it is unknown if this 
increase is dependent on ERα. The upregulation of SSP enzymes can 
contribute to resistance via either glutamine dependence to fuel the TCA cycle 
or through increased one-carbon metabolism to produce SAM. 
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of genetic suppression of PHGDH and PSAT1 that we have observed in this 
chapter. Those results might suggest a combination therapy that may reduce 
resistance and prolong efficacy to tamoxifen therapy. 
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CHAPTER 4 
CONCLUSION 
 In summary, this body of work has demonstrated that PSAT1 contributes to 
the progression of breast cancer in the contexts of TNBC metastasis and ER+BC 
tamoxifen resistance. We have shown that suppression of PSAT1 is able to 
diminish metastatic characteristics in vitro and that loss of PHGDH does not 
recapitulate these results. We have also shown that suppression of PSAT1 inhibits 
tumor nodule formation in an in vivo model of experimental metastasis and that 
this inhibition is not due to a loss of tumorgenicity. The results from our TNBC 
studies suggest a non-canonical role for PSAT1 that selectively inhibits the 
metastatic characteristics of “serine synthesis-independent” TNBC (Chapter 2). 
We have also demonstrated a correlation between higher expression levels 
of PSAT1 and poorer progression-free survival in two distinct ER+BC patient 
cohorts. In addition, we have shown that manipulation of PSAT1 and PHGDH can 
alter sensitivity to tamoxifen treatment in an established sensitive and resistant 
breast cancer cell model system. Our work indicates that these results are due to 
changes in de novo serine synthesis as clinically high expression of PHGDH also 
correlates with poorer progression-free survival and there is increased flux of 
glucose to serine in endocrine resistant cells. We also demonstrated that these 
effects of the SSP enzymes appear to be selective for 4OHT treatment as 
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disruption of the SSP through PSAT1 loss did not alter fulvestrant sensitivity in two 
tamoxifen resistant cell lines. In addition, all clinical significance regarding inverse 
correlation of PSAT1 and PHGDH with relapse-free survival in ER+BC was lost 
upon inclusion of patients treated with any endocrine therapy (Chapter 3).  
My data suggests that the functional roles of PSAT1 as it contributes to 
either metastasis or resistance varies. In the TNBC component of this dissertation, 
PSAT1 is acting independently of its role in serine synthesis as we established that 
PHGDH suppression did not recapitulate PSAT1 suppression. However, in the 
ER+BC portion of this dissertation it seems that the contribution of PSAT1 to 
tamoxifen resistance is associated with its role in serine synthesis as clinically both 
PSAT1 and PHGDH significantly correlated with poorer progression-free survival. 
These results, while conclusive, leave some remaining questions. Primarily, how 
does the expression of a single protein, PSAT1, promote two distinct processes 
(metastasis or endocrine resistance) via two separate mechanisms (canonical vs. 
non-canonical)? In addition, what dictates either canonical or non-canonical 
function of PSAT1 and are these functions mutually exclusive? Lastly, is this 
phenomenon driven exclusively by the proteome differences between TNBC and 
ER+ tamoxifen resistant breast cancer subtypes? 
It is known that there are subtype-specific expression differences for PSAT1 
in other cancer types. It has been shown that PSAT1 is higher in certain ovarian 
cancer subtypes and that PSAT1 expression can be used as a biomarker to 
determine the subtype of ovarian cancer a patient has [78]. In addition, PSAT1 
expression also varies in thyroid cancer subtypes [57]. PSAT1 expression in breast 
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cancer is also known to vary by subtype. PSAT1 protein expression is greater in 
ER- compared to the ER+BC [84,87,94,95]. The lack of expression of PSAT1 in 
ER+BC is mainly due to hypermethylation of the PSAT1 promoter within this 
subtype [94]. This suggests that there might be an ER-dependent silencing of 
PSAT1 within the ER+ subtype that is lost in tumors that are ER-. Previous 
literature would also suggest that this potential ER-dependent regulation is specific 
for PSAT1 and not a regulatory mechanism for the SSP as the differences in 
promoter methylation are specific for PSAT1 [82,94,95] and that both ER+ and ER- 
tumors express PHGDH [87]. 
The role of PSAT1 in metastasis that we have defined in this body of work 
is in a specific subset of TNBC that is “serine-synthesis independent”. This subset 
allowed us to determine if there was a PSAT1 specific role in metastasis that was 
independent from its role in de novo serine synthesis. My data suggests that there 
is a selective role for PSAT1 in breast cancer metastasis. Other groups have also 
found an association between PSAT1 and metastasis that was not found with other 
members of the SSP [85]. This specific association between PSAT1 and 
metastasis has also been observed in several other cancer types. This has been 
observed in nasopharyngeal carcinoma [65] where higher expression of PSAT1 
correlated with poorer local recurrence-free and distant metastatic-free survival. 
Additionally, higher PSAT1 expression was correlated with metastatic 
characteristics [57,58] as well as lymph-node metastasis and distant metastasis in 
esophageal squamous cell carcinoma [72]. While in the report on nasopharyngeal 
carcinoma no mechanism was suggested, the findings in esophageal squamous 
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cell carcinoma also indicated a non-canonical function of PSAT1 in order to 
upregulate the expression/activity of GSK3β and Snail that promoted metastatic 
characteristics in their in vitro studies [72]. 
In addition, there have been numerous accounts of de novo serine 
synthesis implicated in resistance. This has been demonstrated in multiple 
myeloma where higher activity of SSP enzymes was observed in resistant cell 
types and suggested that expression of the SSP enzymes could serve as a 
biomarker for Bortezomib resistance [69]. There has also been a link established 
between SSP and resistance to the BRAF inhibitor Vemurafenib [68]. This was 
observed in melanoma, pancreatic cancer, and non-small cell lung cancer in which 
SSP enzyme expression was higher in resistant cell types which resulted in 
increased proliferation [68]. Our work, as well as previous work [82,97], 
demonstrates that there is a role for the SSP in resistance to tamoxifen in ER+BC 
as higher expression of both PSAT1 and PHGDH correlate to poorer progression-
free survival.  
However, the question remains is the canonical and non-canonical function 
of PSAT1 mutually exclusive and more interestingly, would the metastatic 
characteristics of endocrine resistant cells be solely affected by suppression of 
PSAT1? While these experiments were not performed as a part of this work, there 
is some literature to suggest that these functions are not mutually exclusive and 
that PSAT1 still contributes to metastasis independently of function in de novo 
serine synthesis. Studies completed in models of colon cancer demonstrate that 
there is increased activity of the SSP in colon tumors compared to normal colon 
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tissue [74], especially in patients that were resistant to chemotherapies [75]. 
However, PSAT1 was the singular most upregulated protein in colorectal 
carcinoma patients [75] and specifically increased PSAT1 expression correlated 
with metastasis in resistant patients [73]. We have previously discussed that 
PSAT1 correlates with tamoxifen resistance [82] and that upregulation of PHGDH 
was also found in tamoxifen resistant patients [97] as this was the foundation for 
the studies completed in chapter 3. However, we did not address metastasis in our 
ER+BC studies. Metastasis and its correlation to PSAT1 and PHGDH expression 
in the ER+ tamoxifen resistant setting has been previously studied [97]. In part, 
they found that PSAT1 and not PHGDH correlated with metastasis in ER+ patients 
who are tamoxifen resistant [97]. Both of these findings indicate that PSAT1 can 
simultaneously function within serine synthesis to promote tamoxifen resistance, 
as we have demonstrated, and independently contribute to metastasis as 
observed in our TNBC experiments. 
The question of what dictates the function of PSAT1 remains unknown. This 
could be related to how PSAT1 expression is regulated and/or whether or not 
downstream effectors of PSAT1 that are responsible for either metastasis or 
endocrine resistance are present. Loss of miRNA-dependent suppression of 
PSAT1 resulted in increased protein expression and correlated with metastatic 
disease in two different cancer types [57,58]. Increased demand for serine and the 
resultant one-carbon metabolism products upregulate PSAT1 and de novo serine 
synthesis as a means of ensuring tumor cell survival whilst undergoing therapeutic 
treatment leading to the resistant phenotypes observed. In both of these instances, 
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the upregulation of PSAT1 and the resultant function was determined by a 
combination of events that included additional steps and/or proteins, thus PSAT1 
may be the driver of metastasis and/or endocrine resistance but the determination 
of which process occurs could be decided by which downstream pathways ensure 
the survival of the cancer cell. 
Together, my data suggest that the metastatic phenotype is related to a 
function of PSAT1 that is independent from its role in serine synthesis. It also 
underscores that therapy resistance is reliant upon the serine synthetic pathway 
which is consistent with previous findings that altered methylation patterns 
correlate with resistance and that de novo synthesized serine is used in one-
carbon metabolism. Despite differences in functional roles and reliance on serine, 
this body of work has established that PSAT1 contributes to the progression of 
breast cancer through promoting metastasis in TNBC and resistance to tamoxifen 
in ER+BC. 
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